Ph-sensitive cationic lipid and lipid nanoparticles

A pH-sensitive cationic lipid with three hydrophobic chains, synthesized using tris(hydroxymethyl)aminomethane, addresses the complexity and cost issues of existing lipids by simplifying production and improving delivery efficiency to target cells, enhancing gene expression while reducing production costs.

WO2024248146A1PCT designated stage expired Publication Date: 2024-12-05HOKKAIDO UNIVERSITY

Patent Information

Application Number
PCT/JP2024/020084
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current pH-sensitive cationic lipids for lipid nanoparticles require complex multi-step synthesis and expensive raw materials, making them costly and inefficient for large-scale production, and they face issues with nonspecific interactions with plasma proteins leading to rapid elimination from the blood.

Method used

Development of a pH-sensitive cationic lipid with three hydrophobic chains using tris(hydroxymethyl)aminomethane as a linker, allowing for simpler synthesis and reduced steps without organometallic reactions, and lipid nanoparticles incorporating this lipid for improved stability and targeting efficiency.

Benefits of technology

The new pH-sensitive cationic lipid enables efficient delivery of nucleic acids to target cells by maintaining stability and avoiding rapid elimination, enhancing gene expression and reducing production costs through simplified synthesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024020084_05122024_PF_FP_ABST
    Figure JP2024020084_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are: a pH-sensitive cationic lipid which can be more easily synthesized through a small number of steps without requiring any organometal reaction or use of any relatively expensive starting materials; and lipid nanoparticles including the lipid. Disclosed is a pH-sensitive cationic lipid comprising a compound represented by general formula (I) or (I'). R1, Z2, s, Z1, and X are as defined in the description.
Need to check novelty before this filing date? Find Prior Art

Description

pH-Sensitive Cationic Lipids and Lipid Nanoparticles

[0001] The present invention relates to a pH-sensitive cationic lipid having three hydrophobic chains, and to lipid nanoparticles containing the pH-sensitive cationic lipid.

[0002] Lipid nanoparticles (LNPs) are used as carriers for encapsulating lipid-soluble drugs, nucleic acids such as siRNA (short interfering RNA), and mRNA, and delivering them to target cells. For example, lipid nanoparticles containing pH-sensitive cationic lipids as constituent lipids have been reported as lipid nanoparticles that serve as carriers for efficiently delivering nucleic acids such as siRNA into target cells. These lipid nanoparticles are electrically neutral at physiological pH and change to cationic in a weakly acidic pH environment such as an endosome (Patent Document 1). Lipid nanoparticles that are positively charged in blood undergo nonspecific interactions with plasma proteins and are rapidly eliminated from the blood by the reticuloendothelial system. In contrast, lipid nanoparticles containing pH-sensitive cationic lipids as constituent lipids are uncharged under neutral conditions in blood, but are positively charged under the weakly acidic conditions in endosomes, allowing for efficient endosomal escape.

[0003] As a pH-sensitive cationic lipid, for example, Jayaraman et al. developed DLin-MC3-DMA and demonstrated that it had an EDTA effect in factor 7 (F7) knockdown in mouse liver. 50 The present inventors have also developed their own pH-sensitive cationic lipids YSK05 and YSK13-C3, and have achieved ED of 0.005 mg siRNA / kg in F7 knockdown. 50 The inventors have also developed a pH-sensitive cationic lipid, such as 7-(4-(diisopropylamino)butyl)-7-hydroxytridecane-1,13-diyl dioleate (CL4H6), which has two hydrocarbon chains and one hydrophilic group (Patent Document 1).

[0004] On the other hand, some methods for producing lipid nanoparticles encapsulating nucleic acids, etc., are based on the alcohol dilution method using a flow channel. For example, it has been reported that lipid nanoparticles with a diameter of approximately 30 nm can be reproducibly produced by using a microchannel with a built-in three-dimensional micromixer, which can achieve instantaneous mixing of two liquids (Non-Patent Document 5). It has also been reported that by using a simple two-dimensional flow channel structure in which baffles of a fixed width relative to the flow channel width are arranged alternately on both sides of a micro-sized flow channel through which a raw material solution flows, a nano-sized lipid particle formation system with higher particle size controllability can be formed compared to flow channel structures using conventional three-dimensional mixers (Patent Document 2). These methods for producing nanoparticle formulations have recently been mainly used to produce lipid nanoparticles (LNPs) loaded with lipid-soluble drugs and nucleic acids such as siRNA (short interfering RNA) or mRNA.

[0005] International Publication No. WO 2018 / 230710 International Publication No. WO 2018 / 190423

[0006] Jayaraman et al., Angewandte Chemie International Edition, 2012, vol.51, p.8529-8533.Watanabe et al., Scientific Reports, 2014, 4:4750, DOI: 10.1038 / srep04750.Yamamoto et al., Journal of Hepatology, 2016, vol.64, p.547-555.Sato et al., Molecular Therapy, 2016, vol.24, p.788-795.Leung et al., Journal of Physical Chemistry C Nanomater Interfaces, 2012, vol.116(34), p.18440-18450.

[0007] When mass-producing a compound in a factory, it is preferable to use inexpensive raw materials and synthesize the compound with fewer reaction steps, from the viewpoints of production cost and quality stability. However, the synthesis reaction of pH-sensitive cationic lipids such as CL4H6 described in Patent Document 1 is a multi-step reaction involving six to seven steps, and also requires a Grignard reaction using an organometallic compound. The synthesis reaction of CL4H6 is outlined below.

[0008]

[0009] An object of the present invention is to provide a pH-sensitive cationic lipid that can be synthesized more simply and easily with fewer steps without using organometallic reactions or relatively expensive raw materials, and lipid nanoparticles containing the pH-sensitive cationic lipid.

[0010] The present inventors have discovered that by using tris(hydroxymethyl)aminomethane (CAS number: 77-86-1) (hereinafter abbreviated as "Tris") as a linker, binding hydrocarbon chains to each of the three hydroxy groups of Tris via linking groups that serve as spacers, and binding one hydrophilic group to the amino group of Tris, it is possible to synthesize a pH-sensitive cationic lipid without using relatively expensive raw materials and with a small number of steps, and have completed the present invention.

[0011] That is, the present invention provides, for example, the following pH-sensitive cationic lipids and the like: [1] A compound represented by the following general formula (I) or general formula (I'):

[0012]

[0013] [In formula (I) and formula (I′), R 1 are represented by the following general formulas (T-1) to (T-3):

[0014]

[0015] (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, and R 22 is a hydrocarbon group having 1 to 22 carbon atoms, and R 23 is a hydrocarbon group having 1 to 22 carbon atoms, and R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, and R25 is a hydrocarbon group having 1 to 22 carbon atoms, and R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 and R 22 The sum of the carbon atoms in R is 8 or more, 23 and R 24 The sum of the carbon atoms in R is 6 or more, 25 and R 26 The sum of the carbon atoms in R is 6 or more. The black circles represent bonds. 1 may be the same or different groups; Z 1 represents an alkylene group having 1 to 6 carbon atoms which may be substituted with one hydroxyalkyl group having 1 to 3 carbon atoms, or a single bond; X represents —N(R 2 ) (R 3 ), or a 5- to 7-membered non-aromatic heterocyclic group (provided that the group is not bound by carbon atoms to Z 1 and the ring may be substituted with one or two hydrocarbon groups having 1 to 4 carbon atoms or amide groups; R 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group), and in formula (I), Z 2 is a linear alkylene group or cycloalkylene group having 4 to 6 carbon atoms; 2 may be the same or different groups; and in formula (I'), s is 2, 3, or 4; and the three s's in one molecule may be the same or different numbers. [2] A pH-sensitive cationic lipid comprising a compound represented by the following general formula (I) or general formula (I'): -Z 1-X is represented by the following formulas (H-1) to (H-8) and (H-16) to (H-26):

[0016]

[0017]

[0018] [3] The pH-sensitive cationic lipid according to [1], wherein R 1 [4] The pH-sensitive cationic lipid according to any one of [1] to [3], wherein R is the same group as R. [5] The pH-sensitive cationic lipid according to any one of [1] to [3], wherein R is the same group as R. 1 is represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L):

[0019]

[0020] [wherein the black circle represents a bond.] [6] The pH-sensitive cationic lipid according to any one of [1] to [5] above, which has a pKa of 4.0 to 9.0. [7] The pH-sensitive cationic lipid according to any one of [1] to [6] above, which is selected from the following compounds:

[0021] and

[0022] [8] A method for producing a pH-sensitive cationic lipid, comprising condensing a compound represented by the following general formula (A), a compound represented by the following general formula (B), and tris(hydroxymethyl)aminomethane to produce a pH-sensitive cationic lipid comprising a compound represented by the following general formula (I):

[0023]

[0024] [In the formula, R 1 are represented by the following general formulas (T-1) to (T-3):

[0025]

[0026] (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, and R 22 is a hydrocarbon group having 1 to 22 carbon atoms, and R 23 is a hydrocarbon group having 1 to 22 carbon atoms, and R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, and R 25 is a hydrocarbon group having 1 to 22 carbon atoms, and R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 and R 22 The sum of the carbon atoms in R is 8 or more, 23 and R 24 The sum of the carbon atoms in R is 6 or more, 25 and R 26 The sum of the carbon atoms in the groups is 6 or more. The black circles represent bonds. 2 is a linear alkylene group or cycloalkylene group having 4 to 6 carbon atoms; Z 1 represents an alkylene group having 1 to 6 carbon atoms which may be substituted with one hydroxyalkyl group having 1 to 3 carbon atoms, or a single bond; X represents —N(R 2 ) (R 3 ), or a 5- to 7-membered non-aromatic heterocyclic group (provided that the group is not bound by carbon atoms to Z 1 and the ring may be substituted with one or two hydrocarbon groups or amide groups having 1 to 4 carbon atoms; R 2 and R 3are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group); 1 may be the same or different groups; in general formula (I), three Z 2 may be the same type of group or different types of groups.] [9] A method for producing a pH-sensitive cationic lipid, comprising: condensing a compound represented by the following general formula (A-0) with a compound represented by the following general formula (D) to produce a compound represented by the following general formula (A'): and condensing the compound represented by the general formula (A'), a compound represented by the following general formula (B), and tris(hydroxymethyl)aminomethane to produce a pH-sensitive cationic lipid consisting of a compound represented by the following general formula (I'):

[0027]

[0028]

[0029] [In the formula, R 1 are represented by the following general formulas (T-1) to (T-3):

[0030]

[0031] (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, and R 22 is a hydrocarbon group having 1 to 22 carbon atoms, and R 23 is a hydrocarbon group having 1 to 22 carbon atoms, and R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, and R 25 is a hydrocarbon group having 1 to 22 carbon atoms, and R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms.21 and R 22 The sum of the carbon atoms in R is 8 or more, 23 and R 24 The sum of the carbon atoms in R is 6 or more, 25 and R 26 The sum of the carbon atoms in the groups is 6 or more. The black circles represent bonds.) s is 2, 3, or 4; Z 1 represents an alkylene group having 1 to 6 carbon atoms which may be substituted with one hydroxyalkyl group having 1 to 3 carbon atoms, or a single bond; X represents —N(R 2 ) (R 3 ), or a 5- to 7-membered non-aromatic heterocyclic group (provided that the group is not bound by carbon atoms to Z 1 and the ring may be substituted with one or two hydrocarbon groups or amide groups having 1 to 4 carbon atoms; R 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group); in general formula (I'), three R 1 may be the same or different groups; in general formula (I'), the three s's in one molecule may be the same or different.]

[10] A compound represented by the following general formula (C):

[0032]

[0033] [In the formula, R 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; and one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group)), and then N-[tris(hydroxymethyl)methyl]acrylamide is added to a compound represented by the following general formula (A) or general formula (A'):

[0034]

[0035] [In formula (A) and formula (A'), R 1 are represented by the following general formulas (T-1) to (T-3):

[0036]

[0037] (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, and R 22 is a hydrocarbon group having 1 to 22 carbon atoms, and R 23 is a hydrocarbon group having 1 to 22 carbon atoms, and R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, and R 25 is a hydrocarbon group having 1 to 22 carbon atoms, and R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 and R 22 The sum of the carbon atoms in R is 8 or more, 23 and R 24 The sum of the carbon atoms in R is 6 or more, 25 and R 26 The sum of the carbon atoms in the formula (A) is 6 or more. The black circles represent bonds. 2 is a linear alkylene group or cycloalkylene group having 4 to 6 carbon atoms, and in formula (A'), s is 2, 3, or 4], to obtain a compound represented by the following general formula (I-a) or general formula (I'-a):

[0038]

[0039] [In formula (I-a) and formula (I'-a), R 1 , R 2 and R 3is the same as above; there are three R 1 may be the same or different groups, and in formula (I-a), Z 2 is the same as defined above, and in formula (I'-a), s is the same as defined above.

[0040]

[11] Lipid nanoparticles containing the pH-sensitive cationic lipid of any one of [1] to [7].

[12] Lipid nanoparticles of

[11] further containing a sterol and a polyalkylene glycol-modified lipid.

[13] Lipid nanoparticles of

[11] or

[12] further containing phosphatidylcholine.

[14] Lipid nanoparticles of any one of

[11] to

[13] containing a nucleic acid.

[15] Lipid nanoparticles of

[14] , wherein the nucleic acid is siRNA, mRNA, gRNA, or plasmid DNA.

[16] A pharmaceutical composition comprising, as an active ingredient, lipid nanoparticles containing the pH-sensitive cationic lipid of any one of [1] to [7].

[17] A pharmaceutical composition comprising, as active ingredients, lipid nanoparticles containing the pH-sensitive cationic lipid of any one of [1] to [7] and a nucleic acid.

[18] The pharmaceutical composition of

[16] or

[17] , used in gene therapy.

[19] A method for expressing a foreign gene, comprising administering the lipid nanoparticles of

[14] above, which encapsulate a foreign gene to be expressed in a target cell, to a test animal, thereby expressing the foreign gene in the target cell of the test animal.

[20] A method for expressing a foreign gene, comprising administering the lipid nanoparticles of

[14] above, which encapsulate a foreign gene to be expressed in a target cell of the test animal, to a test animal (excluding humans), thereby expressing the foreign gene in the target cell of the test animal.

[0041] The pH-sensitive cationic lipid according to the present invention is relatively easy to synthesize and suitable for large-scale synthesis, and is therefore useful as a constituent lipid of lipid nanoparticles used as active ingredients in pharmaceuticals.

[0042] 1 shows the results of measuring Fluc activity (RLU / mg protein) in the liver, spleen, kidney, lung, heart, brain, and muscle of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 22. 2 shows the results of measuring Fluc activity (RLU / mg protein) in the liver of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 23. 3 shows the results of measuring Fluc activity (RLU / mg protein) in the spleen of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 23. 4 shows the results of measuring Fluc activity (RLU / mg protein) in the kidney of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 23. 5 shows the results of measuring Fluc activity (RLU / mg protein) in the lung of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 23. 1 shows the results of measuring Fluc activity (RLU / mg protein) in the hearts of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 23. 2 shows the results of measuring Fluc activity (RLU / mg protein) in the livers of mice administered with each Fluc mRNA-loaded lipid nanoparticle in Example 24. 3 shows the results of measuring Fluc activity (RLU / mg protein) in the spleens of mice administered with each Fluc mRNA-loaded lipid nanoparticle in Example 24. 4 shows the results of measuring Fluc activity (RLU / mg protein) in the kidneys of mice administered with each Fluc mRNA-loaded lipid nanoparticle in Example 24. 5 shows the results of measuring Fluc activity (RLU / mg protein) in the lungs of mice administered with each Fluc mRNA-loaded lipid nanoparticle in Example 24. This figure shows the results of measuring Fluc activity (RLU / mg protein) in the hearts of mice administered with each Flu c MRNA-loaded lipid nanoparticle in Example 24. This figure shows the results of measuring Fluc activity (RLU / mg protein) in the livers of mice administered with each Flu c MRNA-loaded lipid nanoparticle in Example 25.26 shows microscopic images (upper row: EGFP, lower row: vascular endothelial cells) of liver sections from mice administered with each EGFP mRNA-loaded lipid nanoparticle in Example 27. 27 shows microscopic images (upper row: EGFP, lower row: vascular endothelial cells) of liver sections from mice administered with each EGFP mRNA-loaded lipid nanoparticle in Example 28. 28 shows the results of measuring Fluc activity (RLU / mg protein) in the livers of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 29. 29 shows the results of measuring human erythropoietin expression levels (hEPO activity) in the serum of mice administered with hEPO mRNA-loaded lipid nanoparticles in Example 30. 29 shows the results of measuring Fluc activity (RLU / mg protein) in the livers of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 30. This figure shows the results of measuring Fluc activity (RLU / mg protein) in the liver, spleen, and lungs of mice administered with Fluc mRNA-loaded lipid nanoparticles in Example 31. This figure shows the results of measuring the TTR amount (μg / mL) and TTR knockdown efficiency (%) in the serum of mice administered with TTR-targeted genome editing lipid nanoparticles loaded with Cas9-mRNA and TTR-gRNA in Example 32. This figure shows the results of measuring the TTR amount (μg / mL) in the serum of mice administered with TTR-targeted genome editing lipid nanoparticles loaded with Cas9-mRNA and TTR-gRNA in Example 33. This figure shows the results of measuring the TTR amount (ng / mL) in the serum of mice administered with PCSK9-targeted genome editing lipid nanoparticles loaded with Cas9-mRNA and PCSK9-gRNA in Example 34.

[0043] Hereinafter, the embodiments of the present invention will be specifically described. In this specification, "X1 to X2 (X1 and X2 are real numbers satisfying X1<X2)" means "X1 or more and X2 or less." X3-X4 (X3 and X4 are integers satisfying X3<X4) means that the number of carbon atoms is X3 or more and X4 or less.

[0044] [pH-sensitive cationic lipid] The pH-sensitive cationic lipid of the present invention is a compound in which a hydrocarbon chain is linked to each of the three oxygen atoms of the Tris backbone via a linking group that serves as a spacer, and a hydrophilic group is bound to one nitrogen atom of the Tris backbone. Here, "Tris backbone" refers to a structure in which one hydrogen atom is removed from each of the three hydroxyl groups and amino group of tris(hydroxymethyl)aminomethane. In other words, the pH-sensitive cationic lipid of the present invention is a compound with three hydrocarbon chains and a hydrophilic portion, and due to its structural similarity, it has a high affinity with lipids such as phospholipids, making it suitable as a constituent lipid of lipid nanoparticles.

[0045] Specifically, the pH-sensitive cationic lipid according to the present invention comprises a compound represented by the following general formula (I) or (I').

[0046]

[0047] In general formulas (I) and (I′), R 1 is a group represented by any one of the following general formulae (T-1) to (T-3): In the formula, the black circle represents a bond.

[0048]

[0049] In general formulas (T-1) to (T-3), R 21 are each independently a hydrocarbon group having 1 to 22 carbon atoms (C 1-22 hydrocarbon group), and R 22 is a hydrocarbon group having 1 to 22 carbon atoms, and R 23 is a hydrocarbon group having 1 to 22 carbon atoms, and R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, and R 25 is a hydrocarbon group having 1 to 22 carbon atoms, and R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 ~R 26 The hydrocarbon group in may be an alkyl group or an alkenyl group. The alkenyl group may be a group having one unsaturated bond, a group having two unsaturated bonds, or a group having three unsaturated bonds.1-22 The hydrocarbon group may be linear or branched.

[0050] R 21 ~R 26 is C 1-22In the case of an alkyl group, examples of the alkyl group include: a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group; an n-pentyl group, a 1-methylbutyl group, a 2-methylbutyl group, a 3-methylbutyl group, a 1-ethylpropyl group, a 1,1-dimethylpropyl group, and a 2,2-dimethylpropyl group; an n-hexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 4-methylpentyl group, a 1-ethylbutyl group, a 1,1-dimethylbutyl group, a 2,2-dimethylbutyl group, a 3,3-dimethylbutyl group, a 1,2-dimethylbutyl group, and a 1-methyl-2,2-dimethylbutyl group; n-heptyl group, 1-methylhexyl group, 2-methylhexyl group, 3-methylhexyl group, 4-methylhexyl group, 5-methylhexyl group, 1-ethylpentyl group, 1,1-dimethylpentyl group, 2,2-dimethylpentyl group, 3,3-dimethylpentyl group, 4,4-dimethylpentyl group, 1-methyl-3,3-dimethylbutyl group, 2-methyl-3,3-dimethylbutyl group; n-octyl group, 1-methylheptyl group, 2-methylheptyl group, 3-methylheptyl group, 4-methylheptyl group, 5-methylheptyl group, 6-methylheptyl group, 1-ethylhexyl group, 1,1-dimethylhexyl group, 2,2-dimethylhexyl group, 3,3-dimethylhexyl group, 4,4-dimethylhexyl group, 5,5-dimethylhexyl group, 1-methyl-4,4-dimethylpentyl group, 2-methyl-4,4-dimethylpentyl group, 3-methyl-4,4-dimethylpentyl group; n-nonyl group, 1-methyloctyl group, 2-methyloctyl group, 3-methyloctyl group, 4-methyloctyl group, 5-methyloctyl group, 6-methyloctyl group, 7-methyloctyl group, 1-ethylheptyl group, 1,1-dimethylheptyl group, 2,2-dimethylheptyl group, 3,3-dimethylheptyl group, 4,4-dimethylheptyl group, 5,5-dimethylheptyl group, 6,6-dimethylheptyl group, 1-methyl-5,5-dimethylhexyl group, 2-methyl-5,5-dimethylhexyl group, 3-methyl-5,5-dimethylhexyl group, 4-methyl-5,5-dimethylhexyl group;n-decyl group, 1-methylnonyl group, 2-methylnonyl group, 3-methylnonyl group, 4-methylnonyl group, 5-methylnonyl group, 6-methylnonyl group, 7-methylnonyl group, 8-methylnonyl group, 1-ethyloctyl group, 1,1-dimethyloctyl group, 2,2-dimethyloctyl group, 3,3-dimethyloctyl group, 4,4-dimethyloctyl group, 5,5-dimethyloctyl group, 6,6-dimethyloctyl group, 7,7-dimethyloctyl group, 1-methyl-6,6-dimethylheptyl group, 2-methyl-6,6-dimethylheptyl group, 3-methyl-6,6-dimethylheptyl group, 4-methyl-6,6-dimethylheptyl group, 5-methyl-6,6-dimethylheptyl group; n-undecyl group, 1-methyldecyl group, 2-methyldecyl group, 3-methyldecyl group, 4-methyldecyl group, 5-methyldecyl group, 6-methyldecyl group, 7-methyldecyl group, 8-methyldecyl group, 9-methyldecyl group, 1-ethylnonyl group, 1,1-dimethylnonyl group, 2,2-dimethylnonyl group, 3,3-dimethylnonyl group, 4,4-dimethylnonyl group, 5,5-dimethylnonyl group, 6,6-dimethylnonyl group, 7,7-dimethylnonyl group, 8,8-dimethylnonyl group, 1-methyl-7,7-dimethyloctyl group, 2-methyl-7,7-dimethyloctyl group, 3-methyl-7,7-dimethyloctyl group, 4-methyl-7,7-dimethyloctyl group, 5-methyl-7,7-dimethyloctyl group, 6-methyl-7,7-dimethyloctyl group;n-dodecyl group, 1-methylundecyl group, 2-methylundecyl group, 3-methylundecyl group, 4-methylundecyl group, 5-methylundecyl group, 6-methylundecyl group, 7-methylundecyl group, 8-methylundecyl group, 9-methylundecyl group, 10-methylundecyl group, 1-ethyldecyl group, 1,1-dimethyldecyl group, 2,2-dimethyldecyl group, 3,3-dimethyldecyl group, 4,4-dimethyldecyl group, 5,5 -dimethyldecyl group, 6,6-dimethyldecyl group, 7,7-dimethyldecyl group, 8,8-dimethyldecyl group, 9,9-dimethyldecyl group, 1-methyl-8,8-dimethylnonyl group, 2-methyl-8,8-dimethylnonyl group, 3-methyl-8,8-dimethylnonyl group, 4-methyl-8,8-dimethylnonyl group, 5-methyl-8,8-dimethylnonyl group, 6-methyl-8,8-dimethylnonyl group, 7-methyl-8,8-dimethylnonyl group; n-Tridecyl group, 1-methyldodecyl group, 2-methyldodecyl group, 3-methyldodecyl group, 4-methyldodecyl group, 5-methyldodecyl group, 6-methyldodecyl group, 7-methyldodecyl group, 8-methyldodecyl group, 9-methyldodecyl group, 10-methyldodecyl group, 11-methyldodecyl group, 1-ethylundecyl group, 1,1-dimethylundecyl group, 2,2-dimethylundecyl group, 3,3-dimethylundecyl group, 4,4-dimethylundecyl group, 5,5-dimethylundecyl group, 6,6-dimethylundecyl group, Methylundecyl group, 7,7-dimethylundecyl group, 8,8-dimethylundecyl group, 9,9-dimethylundecyl group, 10,10-dimethylundecyl group, 1-methyl-9,9-dimethyldecyl group, 2-methyl-9,9-dimethyldecyl group, 3-methyl-9,9-dimethyldecyl group, 4-methyl-9,9-dimethyldecyl group, 5-methyl-9,9-dimethyldecyl group, 6-methyl-9,9-dimethyldecyl group, 7-methyl-9,9-dimethyldecyl group, 8-methyl-9,9-dimethyldecyl group;n-tetradecyl group, 1-methyltridecyl group, 2-methyltridecyl group, 3-methyltridecyl group, 4-methyltridecyl group, 5-methyltridecyl group, 6-methyltridecyl group, 7-methyltridecyl group, 8-methyltridecyl group, 9-methyltridecyl group, 10-methyltridecyl group, 11-methyltridecyl group, 12-methyltridecyl group, 1-ethyldodecyl group, 1,1-dimethyldodecyl group, 2,2-dimethyldodecyl group, 3,3-dimethyldodecyl group, 4,4-dimethyldodecyl group, 5,5-dimethyldodecyl group, 6,6-dimethyldodecyl group, 7,7-dimethyldodecyl group, 8,8-dimethyldodecyl group, 9,9-dimethyldodecyl group, 10,10-dimethyldodecyl group, 11,11-dimethyldodecyl group, 1-methyl-10,10-dimethylundecyl group, 2-methyl-10,10-dimethylundecyl group, 3-methyl-10,10-dimethylundecyl group, 4-methyl-10,10-dimethylundecyl group, 5-methyl-10,10-dimethylundecyl group, 6-methyl-10,10-dimethylundecyl group, 7-methyl-10,10-dimethylundecyl group, 8-methyl-10,10-dimethylundecyl group, 9-methyl-10,10-dimethylundecyl group;n-pentadecyl group, 1-methyltetradecyl group, 2-methyltetradecyl group, 3-methyltetradecyl group, 4-methyltetradecyl group, 5-methyltetradecyl group, 6-methyltetradecyl group, 7-methyltetradecyl group, 8-methyltetradecyl group, 9-methyltetradecyl group, 10-methyltetradecyl group, 11-methyltetradecyl group, 12-methyltetradecyl group, 13-methyltetradecyl group, 1-ethyltridecyl group, 1,1-dimethyltridecyl group, 2,2-dimethyltridecyl group, 3,3-dimethyltridecyl group, 4,4-dimethyltridecyl group, 5,5-dimethyltridecyl group, 6,6-dimethyltridecyl group, 7,7-dimethyltridecyl group, 8 , 8-dimethyltridecyl group, 9,9-dimethyltridecyl group, 10,10-dimethyltridecyl group, 11,11-dimethyltridecyl group, 12,12-dimethyltridecyl group, 1-methyl-11,11-dimethyldodecyl group, 2-methyl-11,11-dimethyldodecyl group, 3-methyl-11,11-dimethyldodecyl group, 4-methyl-11,11-dimethyldodecyl group, 5-methyl-11,11-dimethyldodecyl group, 6-methyl-11,11-dimethyldodecyl group, 7-methyl-11,11-dimethyldodecyl group, 8-methyl-11,11-dimethyldodecyl group, 9-methyl-11,11-dimethyldodecyl group, 10-methyl-11,11-dimethyldodecyl group; n-hexadecyl group, 1-methylpentadecyl group, 2-methylpentadecyl group, 3-methylpentadecyl group, 4-methylpentadecyl group, 5-methylpentadecyl group, 6-methylpentadecyl group, 7-methylpentadecyl group, 8-methylpentadecyl group, 9-methylpentadecyl group, 10-methylpentadecyl group, 11-methylpentadecyl group, 12-methylpentadecyl group, 13-methylpentadecyl group, 14-methylpentadecyl group;n-heptadecyl group, 1-methylhexadecyl group, 2-methylhexadecyl group, 3-methylhexadecyl group, 4-methylhexadecyl group, 5-methylhexadecyl group, 6-methylhexadecyl group, 7-methylhexadecyl group, 8-methylhexadecyl group, 9-methylhexadecyl group, 10-methylhexadecyl group, 11-methylhexadecyl group, 12-methylhexadecyl group, 13-methylhexadecyl group, 14-methylhexadecyl group, 15-methylhexadecyl group; n-octadecyl group, 1-methylheptadecyl group, 2-methylheptadecyl group, 3-methylheptadecyl group, 4-methylheptadecyl group, 5-methylheptadecyl group, 6-methylheptadecyl group, 7-methylheptadecyl group, 8-methylheptadecyl group, 9-methylheptadecyl group, 10-methylheptadecyl group, 11-methylheptadecyl group, 12-methylheptadecyl group, 13-methylheptadecyl group, 14-methylheptadecyl group, 15-methylheptadecyl group, 16-methylheptadecyl group; n-nonadecyl group, 1-methyloctadecyl group, 2-methyloctadecyl group, 3-methyloctadecyl group, 4-methyloctadecyl group, 5-methyloctadecyl group, 6-methyloctadecyl group, 7-methyloctadecyl group, 8-methyloctadecyl group, 9-methyloctadecyl group, 10-methyloctadecyl group, 11-methyloctadecyl group, 12-methyloctadecyl group, 13-methyloctadecyl group, 14-methyloctadecyl group, 15-methyloctadecyl group, 16-methyloctadecyl group, 17-methyloctadecyl group; n-Eicosyl group, 1-methylnonadecyl group, 2-methylnonadecyl group, 3-methylnonadecyl group, 4-methylnonadecyl group, 5-methylnonadecyl group, 6-methylnonadecyl group, 7-methylnonadecyl group, 8-methylnonadecyl group, 9-methylnonadecyl group, 10-methylnonadecyl group, 11-methylnonadecyl group, 12-methylnonadecyl group, 13-methylnonadecyl group, 14-methylnonadecyl group, 15-methylnonadecyl group, 16-methylnonadecyl group, 17-methylnonadecyl group, 18-methylnonadecyl group;n-henicosyl group, 1-methylicosyl group, 2-methylicosyl group, 3-methylicosyl group, 4-methylicosyl group, 5-methylicosyl group, 6-methylicosyl group, 7-methylicosyl group, 8-methylicosyl group, 9-methylicosyl group, 10-methylicosyl group, 11-methylicosyl group, 12-methylicosyl group, 13-methylicosyl group, 14-methylicosyl group, 15-methylicosyl group, 16-methylicosyl group, 17-methylicosyl group, 18-methylicosyl group, 19-methylicosyl group; Examples include n-docosyl group, 1-methylheneicosyl group, 2-methylheneicosyl group, 3-methylheneicosyl group, 4-methylheneicosyl group, 5-methylheneicosyl group, 6-methylheneicosyl group, 7-methylheneicosyl group, 8-methylheneicosyl group, 9-methylheneicosyl group, 10-methylheneicosyl group, 11-methylheneicosyl group, 12-methylheneicosyl group, 13-methylheneicosyl group, 14-methylheneicosyl group, 15-methylheneicosyl group, 16-methylheneicosyl group, 17-methylheneicosyl group, 18-methylheneicosyl group, 19-methylheneicosyl group, and 20-methylheneicosyl group.

[0051] R 21 ~R 26 is C 2-22 In the case of an alkenyl group, the alkenyl group is C 2-22 Examples of the alkyl group include groups in which one to three of the saturated bonds between carbon molecules are unsaturated bonds.

[0052] The three R 1 is a region that interacts with the hydrophobic portion of other lipid molecules that constitute a lipid nanoparticle when the pH-sensitive cationic lipid represented by general formula (I) or (I') is used as a constituent lipid of the lipid nanoparticle. 1 When the hydrocarbon group contained in R is a group consisting of a sufficient number of carbon atoms, the hydrophobic interaction between the pH-sensitive cationic lipid represented by general formula (I) or (I') and other lipid molecules is increased, resulting in lipid nanoparticles that can more stably retain encapsulated substances such as nucleic acids. 1In general formula (T-1), the hydrocarbon group contained in 21 and R 22 In general formula (T-2), R 23 and R 24 In general formula (T-3), R 25 and R 26 is.

[0053] In general formula (T-1), R 21 and R 22 The sum of the carbon atoms in R is 8 or more, preferably 10 or more, and more preferably 12 or more. 21 and R 22 The sum of the carbon numbers of the groups is preferably 28 or less, more preferably 26 or less, and even more preferably 24 or less.

[0054] In general formula (T-2), R 23 and R 24 The sum of the carbon atoms in R is 6 or more, preferably 8 or more, and more preferably 10 or more. 23 and R 24 The sum of the carbon numbers of the above is preferably 26 or less, more preferably 24 or less, and even more preferably 22 or less.

[0055] In general formula (T-3), R 25 and R 26 The sum of the carbon atoms in R is 6 or more, preferably 8 or more, and more preferably 10 or more. 25 and R 26 The sum of the carbon numbers of the above is preferably 26 or less, more preferably 24 or less, and even more preferably 22 or less.

[0056] In general formula (I), Z 2 represents a linear alkylene group having 4 to 6 carbon atoms (linear C 4-6 The cycloalkylene group preferably has 3 to 7 carbon atoms, more preferably 4 to 6 carbon atoms. 2 As the linear C 4-6 An alkylene group is preferred, and a linear alkylene group having 4 or 5 carbon atoms (n-butylene group or n-pentylene group) is particularly preferred. The pH-sensitive cationic lipid represented by general formula (I) is a cationic lipid having a hydrocarbon chain R 1But, the tris skeleton has -CO-Z 2 Since the hydrocarbon chain R 1 has sufficient degrees of freedom.

[0057] In general formula (I'), s is 2, 3, or 4, preferably 2 or 3. In one embodiment, s is 2. In another embodiment, s is 3. In yet another embodiment, s is 4. The pH-sensitive cationic lipid represented by general formula (I') is a cationic lipid having a hydrocarbon chain R 1 But the tris skeleton has -CO-(CH2) s Since the hydrocarbon chain R 1 has sufficient degrees of freedom.

[0058] In the general formulas (I) and (I'), there are three R 1 In terms of ease of synthesis and quality stability, the pH-sensitive cationic lipid according to the present invention is one in which three R 1 are preferably all the same group.

[0059] In general formula (I), there are three Z 2 The pH-sensitive cationic lipid according to the present invention is preferably a lipid having three Z groups in one molecule, from the viewpoint of ease of synthesis and quality stability. 2 are preferably all the same group.

[0060] In general formula (I'), the three s's in one molecule may be the same or different from one another. In terms of ease of synthesis and quality stability, it is preferable that the three s's in one molecule of the pH-sensitive cationic lipid according to the present invention are all the same.

[0061] The pH-sensitive cationic lipid according to the present invention includes R 1is preferably any one of groups represented by the following formulae (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L).

[0062]

[0063]

[0064] In one embodiment, R 1 is preferably any one of groups represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14).

[0065] In the general formulas (I) and (I'), Z 1 is a C optionally substituted with one hydroxy group 1-6 is an alkylene group or a single bond. 1-6 The alkylene group may be linear or branched. 1-6 Examples of the alkylene group include a methylene group, an ethylene group, a 1-methylmethylene group, a 1-hydroxymethylmethylene group, an n-propylene group, a 1-methylethylene group, a 1-hydroxymethylethylene group, a 2-methylethylene group, an n-butylene group, a 1-methylpropylene group, a 1-hydroxymethylpropylene group, a 2-methylpropylene group, a 3-methylpropylene group, a 1-ethylethylene group, a 2-ethylethylene group, an n-pentylene group, a 1-methylbutylene group, a 2-methylbutylene group, a 3-methylbutylene group, a 4-methylbutylene group, a 1-ethylpropylene group, a 2-ethylpropylene group, a 3-ethylpropylene group, an n-hexylene group, a 1-methylpentylene group, a 2-methylpentylene group, a 3-methylpentylene group, a 4-methylpentylene group, a 1-ethylbutylene group, a 2-ethylbutylene group, and a 3-ethylbutylene group. The pH-sensitive cationic lipid according to the present invention includes Z 1is preferably a compound in which Z is a methylene group, an ethylene group, an n-propylene group, a 1-hydroxymethylmethylene group, a 1-methylmethylene group, a 1-methylethylene group, a 1-hydroxymethylethylene group, or a 2-methylethylene group; 1 is a methylene group, an ethylene group, an n-propylene group, or a 1-hydroxymethylmethylene group.

[0066] In the general formulas (I) and (I′), X is —N(R 2 ) (R 3 ), or a 5- to 7-membered non-aromatic heterocyclic group. The 5- to 7-membered non-aromatic heterocyclic group represented by X is connected to Z by a carbon atom. 1 Combine with.

[0067] In the general formulas (I) and (I′), X is —N(R 2 ) (R 3 ), then R 2 and R 3 are each independently a hydrogen atom, or C in which one or two hydrogen atoms may be substituted by a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group. 1-4 It is a hydrocarbon group. 1-4 The hydrocarbon group may be a straight or branched C 1-4 It may be an alkyl group, and may be a straight-chain or branched C 2-4 It may also be an alkenyl group.

[0068] R 2 and R 3 is C 1-4 When it is an alkyl group, the C 1-4 Examples of the alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, an n-butyl group, an isobutyl group, and a tert-butyl group. 2 and R 3 is C 2-4 When the C is an alkenyl group, 2-4 Examples of the alkenyl group include a vinyl group, a 1-propenyl group, a 2-propenyl group, a 1-methylvinyl group, a 2-methyl-1-propenyl group, a 1-butenyl group, a 2-butenyl group, and a 3-butenyl group. The pH-sensitive cationic lipid according to the present invention is a cationic lipid represented by general formula (I) or (I') in which X is -N(R2 ) (R 3 ), then R 2 and R 3 are each independently a hydrogen atom or a linear or branched C 1-4 The compound is preferably an alkyl group, and R 2 and R 3 are each independently a hydrogen atom or a linear C 1-4 More preferred are compounds in which R is an alkyl group. 2 and R 3 are each independently a hydrogen atom, a methyl group, an ethyl group, or an n-propyl group.

[0069] In the general formulas (I) and (I′), X is —N(R 2 ) (R 3 ), then R 2 and R 3 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle. 2 and R 3 Examples of the 5- to 7-membered non-aromatic heterocycle formed by bonding together include a 1-pyrrolidinyl group, a 1-piperidinyl group, a 1-morpholinyl group, and a 1-piperazinyl group.

[0070] X is -N(R 2 ) (R 3 ) and R 2 and R 3 are bonded to each other to form a 5- to 7-membered non-aromatic heterocycle, one or more hydrogen atoms, preferably one or two hydrogen atoms in the 5- to 7-membered non-aromatic heterocycle are C 1-4 It may be substituted with a hydrocarbon group, an amide group, or a nitrogen-containing cyclic group. 1-4 The hydrocarbon group includes C 1-4 Alkyl group or C 2-4 An alkenyl group is preferred. 1-4 Alkyl group or C 2-4When substituted with an alkenyl group, the substituted groups may be the same or different. As the nitrogen-containing cyclic group, a group derived from a ring in which a carbonyl group is adjacent to a nitrogen atom is preferred, such as benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-benzo[d]imidazol-2-one, indolin-2-one, 1,3-dihydro-2H-pyrrol-2-one, 1,3-dihydro-2H-imidazol-2-one, oxazol-2(3H)-one, oxazolidin-2-one, imidazolidin-2-one, pyrrolidin-2-one, 1,4-dihydroisoquinolin-3(2H)-one, 3,4-dihydro-2H-benzo[e][1,3]oxazin-2-one, Examples thereof include groups derived from a nitrogen-containing ring such as 3,4-dihydroquinazolin-2(1H)-one, 3,4-dihydroquinolin-2(1H)-one, 1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one, 3,4-dihydropyridin-2(1H)-one, 3,6-dihydro-pyridin-2(1H)-one, 3,6-dihydro-2H-1,3-oxazin-2-one, 3,4-dihydro-2H-1,3-oxazin-2-one, 3,4-dihydropyrimidin-2(1H)-one, piperidin-2-one, 1,3-oxazinan-2-one, and tetrahydropyrimidin-2(1H)-one.

[0071] X is -N(R 2 ) (R 3 ) and R 2 and R 3 are bonded to each other to form a 5- to 7-membered non-aromatic heterocycle, one of the carbon atoms constituting the 5- to 7-membered non-aromatic heterocycle may be a carbon atom constituting another nitrogen-containing cyclic group. The other nitrogen-containing cyclic group is preferably a group derived from a ring in which a carbonyl group is adjacent to a nitrogen atom, and specific examples thereof include the same groups as those mentioned above.

[0072] In general formulas (I) and (I'), when X is a 5- to 7-membered non-aromatic heterocyclic group, examples of the heteroatom contained in the heterocyclic group include a nitrogen atom, an oxygen atom, and a sulfur atom. The heteroatom constituting the heterocyclic group may be one, or may be two or more heteroatoms that are the same or different. The heterocyclic group may be a saturated heterocyclic ring and may contain one or more double bonds, but the heterocyclic ring is not an aromatic ring.

[0073] When X is a 5- to 7-membered non-aromatic heterocyclic group, the heterocyclic group is bounded by carbon atoms to Z 1 and one or two C 1-4 The hydrocarbon group or amide group may be substituted. 1-4 The hydrocarbon group may be a straight or branched C 1-4 It may be an alkyl group, and may be a straight-chain or branched C 2-4 It may be an alkenyl group. 1-4 Alkyl groups and linear or branched C 2-4 The alkenyl group can be any of those listed above.

[0074] In the general formulas (I) and (I'), -Z 1 -X is preferably any one of the groups of the following formulae (H-1) to (H-8) and (H-16) to (H-26): In the following formulae, a black circle represents a bond.

[0075]

[0076]

[0077] The pH-sensitive cationic lipid according to the present invention includes a cationic lipid represented by the general formula (I): -Z 1 -X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), and Z 2 is a linear C 4-6 is an alkylene group, and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), and Z 2 is an n-butylene group, and -Z 1 -X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26), or in general formula (I), R 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), and Z 2 is an n-pentylene group, and -Z 1 Even more preferred are compounds in which —X is any of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26).

[0078] In one embodiment, in general formula (I), R 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), and Z 2 is a linear C 4-6 is an alkylene group, and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), and Z 2 is an n-butylene group, and -Z 1 -X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26), or in general formula (I), R 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), and Z 2 is an n-pentylene group, and -Z 1 Even more preferred are compounds in which —X is any of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26).

[0079] The pH-sensitive cationic lipid according to the present invention includes a compound represented by general formula (I'): -Z 1 -X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26). In general formula (I'), R1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), s is 2 or 3, and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), s is 2, and -Z 1 -X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26), or in general formula (I'), R 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L), s is 3, and -Z 1 Even more preferred are compounds in which —X is any of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26).

[0080] In one embodiment, in general formula (I′), R 1is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), s is 2 or 3, and -Z 1 More preferred are compounds in which —X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26); 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), s is 2, and -Z 1 -X is any one of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26), or in general formula (I'), R 1 is a group represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), or (E14), s is 3, and -Z 1 Even more preferred are compounds in which —X is any of the groups of formulae (H-1) to (H-8) and (H-16) to (H-26).

[0081] The pH-sensitive cationic lipid of the present invention has one tris backbone and three R 1 A hydrocarbon chain consisting of the following is extended via a spacer, and the tris skeleton further comprises Z 1 Therefore, in the pH-sensitive cationic lipid according to the present invention, the hydrophilic group consisting of X is linked via R 1The pH-sensitive cationic lipid of the present invention can be oriented such that it is sterically shielded by three hydrocarbon chains consisting of the three hydrocarbon chains. On the other hand, the pH-sensitive cationic lipids described in Patent Document 1, such as CL4H6, have two hydrophobic chains and a hydrophilic group, and are positioned such that the hydrophilic group and the hydrophobic chain are separated from each other. Due to these differences in three-dimensional structure, when used as a constituent lipid of lipid nanoparticles, the pH-sensitive cationic lipid of the present invention can be expected to have properties different from those of conventional pH-sensitive cationic lipids such as CL4H6.

[0082] The pKa of the pH-sensitive cationic lipid represented by general formula (I) or (I') is not particularly limited, but can be selected, for example, from about 4.0 to 9.0, preferably from about 4.5 to 8.5, and more preferably from about 5.0 to 8.5, and it is preferable to select the type of each substituent so as to give a pKa within this range. The pKa of the pH-sensitive cationic lipid is particularly determined by the -Z in general formula (I) and (I'). 1 For example, -Z in the general formulas (I) and (I') 1 By selecting a group of formulas (H-1) to (H-8) and (H-16) to (H-26) that has a pKa value close to the desired value for —X, a pH-sensitive cationic lipid having a desired pKa value can be obtained.

[0083] The pH-sensitive cationic lipid according to the present invention can be produced, for example, by condensing a compound represented by the following general formula (A) (hereinafter sometimes referred to as "compound (A)"), a compound represented by the following general formula (B) (hereinafter sometimes referred to as "compound (B)"), and tris(hydroxymethyl)aminomethane. 1 and Z 2 respectively represent R in general formula (I). 1 and Z 2 Z in general formula (B) is the same as 1 and X are Z in general formula (I), respectively. 1 and X.

[0084]

[0085] The carboxylic acid group of compound (A) and the hydroxy group of Tris are dehydration condensed to form an ester bond, and then the carboxylic acid group of compound (B) and the amino group of Tris are dehydration condensed to form an amide bond, thereby synthesizing a pH-sensitive cationic lipid represented by general formula (I).The dehydration condensation reaction between the carboxylic acid group of compound (A) and the hydroxy group of Tris can generally be carried out under the same reaction conditions as the dehydration condensation reaction when forming an esterified product of carboxylic acid and alcohol.The dehydration condensation reaction between the carboxylic acid group of compound (B) and the amino group of Tris can generally be carried out under the same reaction conditions as the dehydration condensation reaction when forming an amidated product of carboxylic acid and amine.That is, the pH-sensitive cationic lipid represented by general formula (I) can be synthesized relatively easily by using Tris as a linker through a general dehydration condensation reaction.

[0086] The pH-sensitive cationic lipid represented by general formula (I) can be synthesized by reacting compound (A) with Tris, carrying out dehydration condensation reaction with the hydroxyl group of Tris, then reacting compound (B) with the obtained esterified product, carrying out dehydration condensation reaction with the amino group derived from Tris.In addition, the pH-sensitive cationic lipid represented by general formula (I) can also be synthesized by reacting compound (B) with Tris, carrying out dehydration condensation reaction with the amino group of Tris, then reacting compound (A) with the obtained amidated product, carrying out dehydration condensation reaction with the hydroxyl group derived from Tris.

[0087] Z in compound (A) 2 is a linear C 2-4 A compound in which R is an alkylene group, i.e., a compound represented by the following general formula (A') (hereinafter, sometimes referred to as "compound (A')"), can be produced by ring-opening condensation of a compound represented by the following general formula (A-0) with a dicarboxylic acid anhydride represented by the following general formula (D) (hereinafter, sometimes referred to as "compound (D)"). In general formula (A-0), R 1 is the same as in general formula (A). In general formula (A'), s represents 2, 3, or 4. s in general formula (D) is the same as s in general formula (A').

[0088]

[0089] The ring-opening condensation reaction of compound (A-0) and compound (D) can generally be carried out under reaction conditions similar to those of a dehydration condensation reaction in forming an amidation product between an acid anhydride and a primary or secondary amine, or a dehydration condensation reaction in forming an esterification product between an acid anhydride and an alcohol.

[0090] The carboxylic acid group of the produced compound (A') and the hydroxy group of Tris are subjected to dehydration condensation to form an ester bond, and the carboxylic acid group of compound (B) and the amino group of Tris are subjected to dehydration condensation to form an amide bond, thereby synthesizing the pH-sensitive cationic lipid represented by general formula (I').

[0091]

[0092] Among the pH-sensitive cationic lipids represented by general formula (I) or (I'), Z 1 is an ethylene group, and X is —N(R 2 ) (R 3 ) (compounds represented by general formula (I-a) or general formula (I'-a)) can be synthesized by a simpler synthesis method using, for example, N-[tris(hydroxymethyl)methyl]acrylamide. Specifically, they can be produced by adding N-[tris(hydroxymethyl)methyl]acrylamide to a compound represented by general formula (C), and then condensing the resulting compound represented by general formula (E) with a compound represented by general formula (A) or general formula (A').

[0093]

[0094]

[0095] R in general formula (C) 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3may bond with each other to form a 5- to 7-membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group). 2 and R 3 respectively represent R in general formula (C). 2 and R 3 is the same as

[0096] R in general formula (A) 1 and Z 2 respectively represent R in general formula (I). 1 and Z 2 R in general formula (A') is the same as 1 and s are R in general formula (I'), 1 and s.

[0097] In general formula (I-a), R 1 and Z 2 respectively represent R in general formula (I). 1 and Z 2 is the same as R 2 and R 3 respectively represent R in general formula (C). 2 and R 3 R in general formula (I'-a) is the same as 1 and s are R in general formula (I'), 1 and s are the same as R 2 and R 3 respectively represent R in general formula (C). 2 and R 3 is the same as

[0098] The addition reaction of a compound represented by general formula (C) to the unsaturated bond in N-[tris(hydroxymethyl)methyl]acrylamide can generally be carried out under reaction conditions similar to those used in addition reactions when adding a secondary amine to an alkene. The dehydration condensation reaction between the carboxylic acid group of a compound represented by general formula (A) or general formula (A') and the hydroxy group of a compound represented by general formula (E) can generally be carried out under reaction conditions similar to those used in dehydration condensation reactions when forming an ester of a carboxylic acid and an alcohol. In other words, the pH-sensitive cationic lipid represented by general formula (I-a) or general formula (I'-a) can be synthesized relatively easily by using N-[tris(hydroxymethyl)methyl]acrylamide through a typical addition reaction and dehydration condensation reaction.

[0099] The pH-sensitive cationic lipid represented by general formula (I) or (I') can be easily produced, for example, by the method specifically shown in the Examples of this specification. By referring to this production method and appropriately selecting raw material compounds, reagents, reaction conditions, etc., a person skilled in the art can easily produce any lipid falling within the scope of general formula (I) or (I').

[0100] [Lipid nanoparticles] The lipid nanoparticles according to the present invention have the pH-sensitive cationic lipid according to the present invention as a constituent lipid. The pH-sensitive cationic lipid according to the present invention constituting the lipid nanoparticles according to the present invention may be of only one type, or may be of two or more types. When the pH-sensitive cationic lipid according to the present invention constituting the lipid nanoparticles according to the present invention is of two or more types, the amount of the pH-sensitive cationic lipid according to the present invention means the total amount of lipid molecules corresponding to the pH-sensitive cationic lipid according to the present invention among the lipid molecules constituting the lipid nanoparticles.

[0101] The ratio of the pH-sensitive cationic lipid according to the present invention to the lipid molecules constituting the lipid nanoparticles is not particularly limited. For example, in the lipid nanoparticles according to the present invention, the ratio of the amount of the pH-sensitive cationic lipid according to the present invention to the total amount of lipids constituting the lipid nanoparticles ([amount of pH-sensitive cationic lipid according to the present invention (mol)] / ([total amount of lipids constituting the lipid nanoparticles (mol)]) × 100%) is preferably 5 mol% or more, more preferably 10 mol% or more, and even more preferably 20 mol% or more. On the other hand, if the ratio of the pH-sensitive cationic lipid to the lipid molecules constituting the lipid nanoparticles is too high, the content of other lipids required to impart the desired properties to the lipid nanoparticles may be too low. For this reason, the ratio of the amount of the pH-sensitive cationic lipid according to the present invention to the total amount of lipids constituting the lipid nanoparticles in the lipid nanoparticles according to the present invention is preferably 90 mol% or less, more preferably 80 mol% or less, and even more preferably 70 mol% or less.

[0102] Among the constituent lipids of the lipid nanoparticles of the present invention, lipids other than the pH-sensitive cationic lipid of the present invention can be lipids generally used in forming liposomes. Examples of such lipids include phospholipids, sterols, glycolipids, saturated or unsaturated fatty acids, etc. These can be used alone or in combination of two or more.

[0103] Examples of phospholipids include glycerophospholipids such as phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylcholine, cardiolipin, plasmalogen, ceramide phosphorylglycerol phosphate, and phosphatidic acid; and sphingophospholipids such as sphingomyelin, ceramide phosphorylglycerol, and ceramide phosphorylethanolamine. Phospholipids derived from natural products such as egg yolk lecithin and soybean lecithin can also be used. The fatty acid residues in the glycerophospholipids and sphingophospholipids are not particularly limited, and examples thereof include saturated or unsaturated fatty acid residues having 12 to 24 carbon atoms, with saturated or unsaturated fatty acid residues having 14 to 20 carbon atoms being preferred. Specific examples include acyl groups derived from fatty acids such as lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidic acid, arachidonic acid, behenic acid, lignoceric acid, etc. When these glycerolipids or sphingolipids have two or more fatty acid residues, all of the fatty acid residues may be the same group or may be different groups.

[0104] Examples of sterols include animal-derived sterols such as cholesterol, cholesterol succinate, lanosterol, dihydrolanosterol, desmosterol, and dihydrocholesterol; plant-derived sterols (phytosterols) such as stigmasterol, sitosterol, campesterol, and brassicasterol; and microbial-derived sterols such as zymosterol and ergosterol. Examples of glycolipids include glyceroglycolipids such as sulfoxyribosylglyceride, diglycosyldiglyceride, digalactosyldiglyceride, galactosyldiglyceride, and glycosyldiglyceride; and sphingoglycolipids such as galactosylcerebroside, lactosylcerebroside, and ganglioside. Examples of saturated or unsaturated fatty acids include saturated or unsaturated fatty acids having 12 to 20 carbon atoms such as palmitic acid, oleic acid, stearic acid, arachidonic acid, and myristic acid.

[0105] The constituent lipids of the lipid nanoparticles of the present invention preferably contain a neutral lipid in addition to the pH-sensitive cationic lipid of the present invention, more preferably a phospholipid or a sterol, even more preferably a sterol, and even more preferably cholesterol.

[0106] The lipid nanoparticles according to the present invention preferably contain a polyalkylene glycol-modified lipid as a lipid component. Polyalkylene glycol is a hydrophilic polymer, and by constructing lipid nanoparticles using a polyalkylene glycol-modified lipid as a lipid membrane-constituting lipid, the surface of the lipid nanoparticles can be modified with polyalkylene glycol. Surface modification with polyalkylene glycol may improve the stability of the lipid nanoparticles, such as their blood retention.

[0107] Examples of polyalkylene glycols that can be used include polyethylene glycol, polypropylene glycol, polytetramethylene glycol, polyhexamethylene glycol, etc. The molecular weight of the polyalkylene glycol is, for example, about 300 to 10,000, preferably about 500 to 10,000, and more preferably about 1,000 to 5,000.

[0108] For example, stearylated polyethylene glycol (e.g., PEG 45 stearate (STR-PEG45)) can be used to modify lipids with polyethylene glycol. Other examples include N-[carbonyl-methoxypolyethylene glycol-2000]-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, n-[carbonyl-methoxypolyethylene glycol-5000]-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, N-[carbonyl-methoxypolyethylene glycol-750]-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and N-[carbonyl-methoxypolyethylene glycol- Polyethylene glycol derivatives such as N-[carbonyl-methoxypolyethylene glycol-5000]-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, N-[carbonyl-methoxypolyethylene glycol-5000]-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG-DMG) can also be used, but the polyalkylene glycolated lipid is not limited to these.

[0109] The ratio of the polyalkylene glycol-modified lipid to the total amount of lipids constituting the lipid nanoparticles of the present invention is not particularly limited, as long as it is an amount that does not impair the target tissue selectivity of the pH-sensitive cationic lipid of the present invention, specifically, the target tissue-specific gene expression activity when the lipid nanoparticles of the present invention are used as gene expression carriers. For example, the ratio of the polyalkylene glycol-modified lipid to the total amount of lipids constituting the lipid nanoparticles is preferably 0.5 to 3 mol%.

[0110] The lipid nanoparticles according to the present invention can be subjected to appropriate surface modification, etc., as necessary. The lipid nanoparticles according to the present invention can have improved blood retention by modifying the surface with a hydrophilic polymer or the like. Surface modification can sometimes be achieved by using lipids modified with these modifying groups as constituent lipids of the lipid nanoparticles.

[0111] In producing the lipid nanoparticles according to the present invention, examples of lipid derivatives that can be used to enhance blood retention include glycophorin, ganglioside GM1, phosphatidylinositol, ganglioside GM3, glucuronic acid derivatives, glutamic acid derivatives, polyglycerin phospholipid derivatives, etc. Furthermore, in addition to polyalkylene glycols, hydrophilic polymers that can be used for surface modification to enhance blood retention include dextran, pullulan, ficoll, polyvinyl alcohol, styrene-maleic anhydride alternating copolymer, divinyl ether-maleic anhydride alternating copolymer, amylose, amylopectin, chitosan, mannan, cyclodextrin, pectin, and carrageenan.

[0112] Furthermore, to promote nuclear translocation of the lipid nanoparticles according to the present invention, the surface of the lipid nanoparticles can be modified with, for example, an oligosaccharide compound of three or more sugars. The type of oligosaccharide compound of three or more sugars is not particularly limited, but for example, an oligosaccharide compound having about 3 to 10 sugar units bonded thereto can be used, and preferably an oligosaccharide compound having about 3 to 6 sugar units bonded thereto can be used. Among these, oligosaccharide compounds that are glucose trimers or hexamers are preferred, and oligosaccharide compounds that are glucose trimers or tetramers are even more preferred. More specifically, isomaltotriose, isopanose, maltotriose, maltotetraose, maltopentaose, or maltohexaose are suitable for use, and among these, maltotriose, maltotetraose, maltopentaose, or maltohexaose in which glucose is α1-4-linked are even more preferred. Maltotriose or maltotetraose are particularly preferred, and maltotriose is the most preferred. The amount of surface modification of lipid nanoparticles with an oligosaccharide compound is not particularly limited, but is, for example, about 1 to 30 mol %, preferably about 2 to 20 mol %, and more preferably about 5 to 10 mol % of the total lipid amount.

[0113] The method for surface-modifying lipid nanoparticles with oligosaccharide compounds is not particularly limited, but for example, liposomes in which the surface of lipid nanoparticles is modified with monosaccharides such as galactose or mannose (WO 2007 / 102481) are known, and the surface modification method described in this publication can be adopted. The disclosure of the above publication is incorporated herein by reference in its entirety.

[0114] Furthermore, the lipid nanoparticles according to the present invention can be imparted with one or more of the following functions: temperature sensitivity, membrane permeability, gene expression, and pH sensitivity. By appropriately imparting these functions, the retention of the lipid nanoparticles in the blood can be improved, and the lipid nanoparticles can be efficiently released from endosomes after endocytosis in target cells, allowing the encapsulated nucleic acid to be more efficiently expressed in the target cells.

[0115] The lipid nanoparticles of the present invention may contain one or more substances selected from the group consisting of antioxidants such as tocopherol, propyl gallate, ascorbyl palmitate, or butylated hydroxytoluene, charged substances, and membrane polypeptides. Examples of charged substances that impart a positive charge include saturated or unsaturated aliphatic amines such as stearylamine and oleylamine. Examples of charged substances that impart a negative charge include dicetyl phosphate, cholesteryl hemisuccinate, phosphatidylserine, phosphatidylinositol, and phosphatidic acid. Examples of membrane polypeptides include membrane surface polypeptides and membrane integral polypeptides. The amounts of these substances to be incorporated are not particularly limited and can be selected appropriately depending on the purpose.

[0116] The size of the lipid nanoparticles according to the present invention is preferably an average particle diameter of 450 nm or less, more preferably an average particle diameter of 300 nm or less, even more preferably an average particle diameter of 200 nm or less, and even more preferably an average particle diameter of 160 nm or less, since this facilitates high delivery efficiency to target cells in vivo. The average particle diameter of the lipid nanoparticles refers to the number-average particle diameter measured by dynamic light scattering (DLS). Measurement by dynamic light scattering can be carried out by conventional methods using a commercially available DLS device or the like.

[0117] The polydispersity index (PDI) of the lipid nanoparticles according to the present invention is about 0.01 to 0.7, preferably about 0.01 to 0.6, more preferably about 0.01 to 0.45, and even more preferably about 0.01 to 0.3. The zeta (ζ) potential can be in the range of -50 mV to 5 mV, preferably -40 mV to 5 mV, more preferably -20 mV to 5 mV, and even more preferably -12 mV to 5 mV.

[0118] The form of the lipid nanoparticles according to the present invention is not particularly limited, and examples thereof include unilamellar liposomes, multilamellar liposomes, spherical micelles, irregular layered structures, etc. The lipid nanoparticles according to the present invention are preferably unilamellar liposomes or multilamellar liposomes when dispersed in an aqueous solvent.

[0119] The lipid nanoparticles according to the present invention preferably contain a target component to be delivered into target cells within the lipid membrane-covered particles. The component contained within the lipid nanoparticles according to the present invention is not particularly limited as long as it has a size that allows it to be contained. The lipid nanoparticles according to the present invention can contain any substance, such as nucleic acids, sugars, peptides, low-molecular-weight compounds, and metal compounds.

[0120] The component to be encapsulated in the lipid nanoparticles according to the present invention is preferably a nucleic acid. The nucleic acid may be DNA, RNA, or an analog or derivative thereof (e.g., peptide nucleic acid (PNA) or phosphorothioate DNA). The nucleic acid to be encapsulated in the lipid nanoparticles according to the present invention may be a single-stranded nucleic acid, a double-stranded nucleic acid, linear, or cyclic.

[0121] The nucleic acid to be encapsulated in the lipid nanoparticles of the present invention preferably contains a foreign gene for expression in the target cell, and more preferably is a nucleic acid that functions to express the foreign gene in the cell by being incorporated into the cell. The foreign gene may be a gene that is originally contained in the genomic DNA of the target cell, or a gene that is not contained in the genomic DNA. Examples of such nucleic acids include gene expression vectors containing a nucleic acid consisting of a base sequence encoding the target gene to be expressed. The gene expression vector may exist as an extrachromosomal gene in the introduced cell, or may be incorporated into the genomic DNA by homologous recombination.

[0122] The gene expression vector to be encapsulated in the lipid nanoparticles of the present invention is not particularly limited, and vectors commonly used in gene therapy, etc. can be used. The gene expression vector to be encapsulated in the lipid nanoparticles of the present invention is preferably a nucleic acid vector such as a plasmid vector. The plasmid vector may remain circular, or may be encapsulated in the lipid nanoparticles of the present invention after being pre-cleaved into a linear form. The gene expression vector can be designed by standard methods using commonly used molecular biology tools based on the base sequence information of the gene to be expressed, and can be produced by various known methods.

[0123] The nucleic acid to be encapsulated in the lipid nanoparticles according to the present invention is preferably a functional nucleic acid that controls the expression of a target gene present in a target cell. Examples of such functional nucleic acids include antisense oligonucleotides, antisense DNA, antisense RNA, siRNA, microRNA, mRNA, gRNA, etc. The nucleic acid may also be a plasmid DNA (pDNA) that serves as an expression vector, such as an siRNA expression vector, that expresses siRNA in cells. The expression vector can be prepared from a commercially available one and modified as appropriate. For example, an siRNA expression vector can be prepared from a commercially available siRNA expression vector, which may also be modified as appropriate. The nucleic acid to be encapsulated in the lipid nanoparticles according to the present invention is preferably mRNA or pDNA, as these have particularly good selectivity for tissues in the body.

[0124] The method for producing lipid nanoparticles according to the present invention is not particularly limited, and any method available to those skilled in the art can be employed. For example, all lipid components are dissolved in an organic solvent such as chloroform, and a lipid membrane is formed by drying under reduced pressure using an evaporator or spray drying using a spray dryer. An aqueous solvent containing the components to be encapsulated in the lipid nanoparticles, such as nucleic acids, is then added to the dried mixture, and the resulting mixture is emulsified using an emulsifier such as a homogenizer, an ultrasonic emulsifier, or a high-pressure injection emulsifier. Liposomes can also be produced by well-known methods for producing liposomes, such as reverse-phase evaporation. To control the size of lipid nanoparticles, extrusion filtration can be performed under high pressure using a membrane filter with a uniform pore size.

[0125] The composition of the aqueous solvent (dispersion medium) is not particularly limited, and examples thereof include buffer solutions such as phosphate buffer, citrate buffer, and phosphate-buffered saline, physiological saline, cell culture media, etc. These aqueous solvents (dispersion media) can stably disperse lipid nanoparticles, but may also contain sugars (aqueous solutions) such as monosaccharides such as glucose, galactose, mannose, fructose, inositol, ribose, and xylose, disaccharides such as lactose, sucrose, cellobiose, trehalose, and maltose, trisaccharides such as raffinose and melezinose, polysaccharides such as cyclodextrin, sugar alcohols such as erythritol, xylitol, sorbitol, mannitol, and maltitol, and polyhydric alcohols (aqueous solutions) such as glycerin, diglycerin, polyglycerin, propylene glycol, polypropylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, ethylene glycol monoalkyl ethers, diethylene glycol monoalkyl ethers, and 1,3-butylene glycol. To stably store lipid nanoparticles dispersed in this aqueous solvent for a long period of time, it is desirable to eliminate electrolytes from the aqueous solvent as much as possible from the viewpoint of physical stability such as suppressing aggregation. Also, from the viewpoint of chemical stability of lipids, it is desirable to set the pH of the aqueous solvent to a weakly acidic to near-neutral range (pH 3.0 to 8.0) and / or remove dissolved oxygen by nitrogen bubbling or the like.

[0126] The lipid nanoparticles of the present invention can also be produced by an alcohol dilution method using a flow channel. This method involves introducing a solution of lipid components dissolved in an alcohol solvent and a solution of water-soluble components to be incorporated into the lipid nanoparticles into an aqueous solvent through separate flow channels and then merging them to produce lipid nanoparticles. By using a microchannel with a built-in three-dimensional micromixer, which can achieve instantaneous mixing of the two liquids, lipid nanoparticles with a diameter of approximately 30 nm can be reproducibly produced (Non-Patent Document 5). As the flow channel used for production, a simple two-dimensional flow channel structure, such as that described in Patent Document 2, in which a micro-sized flow channel for flowing a raw solution is provided with baffles (baffles) of a fixed width arranged alternately on both sides of the flow channel, can be used, as this allows for the formation of a nano-sized lipid particle formation system with high particle size controllability. The aqueous solvent used in the alcohol dilution method can be the same as described above.

[0127] When the obtained aqueous dispersion of lipid nanoparticles is freeze-dried or spray-dried, stability may be improved by using a sugar (aqueous solution) such as monosaccharides such as glucose, galactose, mannose, fructose, inositol, ribose, and xylose, disaccharides such as lactose, sucrose, cellobiose, trehalose, and maltose, trisaccharides such as raffinose and melezinose, polysaccharides such as cyclodextrin, and sugar alcohols such as erythritol, xylitol, sorbitol, mannitol, and maltitol. Furthermore, when the aqueous dispersion is frozen, stability may be improved by using a polyhydric alcohol (aqueous solution) such as the above-mentioned sugars or glycerin, diglycerin, polyglycerin, propylene glycol, polypropylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, ethylene glycol monoalkyl ethers, diethylene glycol monoalkyl ethers, and 1,3-butylene glycol.

[0128] The lipid nanoparticles according to the present invention function as gene expression carriers for target tissues. By encapsulating a foreign gene to be expressed in target cells in the lipid nanoparticles according to the present invention and then administering the nanoparticles to a test animal, the foreign gene is expressed in the target tissue of the test animal. The lipid nanoparticles according to the present invention can also encapsulate medicinal ingredients other than nucleic acids and deliver the medicinal ingredients to target tissues, making them useful as drug transport carriers. Therefore, the lipid nanoparticles according to the present invention are useful as active ingredients in pharmaceutical compositions used in various treatments, including gene therapy.

[0129] Lipid nanoparticles with high liver selectivity can be produced by using a compound with high liver tissue specificity from the pH-sensitive cationic lipids of the present invention as the constituent lipid, and selecting lipids that are easily taken up by the liver from the other constituent lipids. Similarly, lipid nanoparticles with high spleen selectivity can be produced by using a compound with high spleen tissue specificity from the pH-sensitive cationic lipids of the present invention as the constituent lipid, and selecting lipids that are easily taken up by the spleen from the other constituent lipids. When such lipid nanoparticles with high liver selectivity or lipid nanoparticles with high spleen selectivity encapsulated with a gene expression vector are administered to an animal, the gene expression vector encapsulated in the lipid nanoparticles is selectively expressed in the liver or spleen over other organs. Similarly, when lipid nanoparticles with high liver selectivity or lipid nanoparticles with high spleen selectivity encapsulated with an siRNA expression vector are administered to an animal, the siRNA expression vector encapsulated in the lipid nanoparticles is selectively expressed in the liver or spleen over other organs, and expression of the gene targeted by the expression vector is suppressed.

[0130] Lipid nanoparticles with high liver selectivity include those in which the content of phosphatidylcholine in the total constituent lipids is 10 mol% or less, preferably 2 to 9 mol%, more preferably 2 to 5 mol%, and even more preferably 2 to 4 mol%.

[0131] The animals to which the lipid nanoparticles of the present invention are administered are not particularly limited, and may be humans or non-human animals. Non-human animals include mammals such as cows, pigs, horses, sheep, goats, monkeys, dogs, cats, rabbits, mice, rats, hamsters, and guinea pigs, as well as birds such as chickens, quails, and ducks. The route of administration of the lipid nanoparticles of the present invention to animals is not particularly limited, but is preferably parenteral, such as intravenous administration, enteral administration, intramuscular administration, subcutaneous administration, transdermal administration, nasal administration, or pulmonary administration.

[0132] In one aspect, the lipid nanoparticles of the present invention are lipid nanoparticles containing a pH-sensitive cationic lipid as described herein for use as a pharmaceutical. Also, in another aspect, the lipid nanoparticles of the present invention are lipid nanoparticles containing a pH-sensitive cationic lipid as described herein and a nucleic acid for use as a pharmaceutical.

[0133] In one aspect, the lipid nanoparticles of the present invention are lipid nanoparticles containing a pH-sensitive cationic lipid as described herein for use in gene therapy. Also, in another aspect, the lipid nanoparticles of the present invention are lipid nanoparticles containing a pH-sensitive cationic lipid as described herein and a nucleic acid for use in gene therapy.

[0134] In one aspect, the lipid nanoparticles of the present invention are lipid nanoparticles that contain the pH-sensitive cationic lipid described herein and encapsulate a foreign gene to be expressed in a target cell, and a method for expressing the foreign gene in a target cell of a subject animal is provided, the method comprising administering the lipid nanoparticles to the subject animal.

[0135] In one aspect, the lipid nanoparticles of the present invention are lipid nanoparticles that contain a pH-sensitive cationic lipid described herein and encapsulate a nucleic acid that can inhibit the function of a target gene, and a method for inhibiting the function of the target gene is provided, which comprises administering the lipid nanoparticles to a subject animal.

[0136] In one aspect, the lipid nanoparticles according to the present invention are lipid nanoparticles containing a pH-sensitive cationic lipid and a nucleic acid as described herein, and the lipid nanoparticles can be used in a method for treating or preventing a disease associated with a genetic abnormality. Specifically, a method for treating or preventing a disease associated with a genetic abnormality is provided, which comprises administering to a subject in need of such treatment or prevention lipid nanoparticles containing a pH-sensitive cationic lipid and a nucleic acid as described herein, wherein the nucleic acid suppresses or replaces the function of the gene.

[0137] In one aspect, the lipid nanoparticles according to the present invention can be used in the manufacture of a medicament for gene therapy. Specifically, there is provided a use of lipid nanoparticles containing a pH-sensitive cationic lipid as described herein in the manufacture of a medicament for gene therapy. There is also provided a use of lipid nanoparticles containing a pH-sensitive cationic lipid and a nucleic acid as described herein in the manufacture of a medicament for gene therapy.

[0138] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.

[0139] <NMR> In the following experiments, unless otherwise specified, 1 H and 13 C NMR spectra were obtained using a JEOL NMR instrument (ECA500 or ECS400) with tetramethylsilane as the internal standard (0 ppm). d stands for doublet, t for triplet, and m for multiplet. 1 Chemical shifts for H NMR spectra were reported in ppm, downfield from tetramethylsilane, on the σ scale.

[0140] Thin-Layer Chromatography (TLC) In the following experiments, unless otherwise noted, all reactions were monitored by TLC using precoated TLC plates (Millipore). TLC visualization was performed using UV light (254 nm), phosphomolybdic acid staining, or staining with p-anisaldehyde, iodine, or Dragendorff's reagent. Reaction products were purified using the Selekt system (Biotage).

[0141] <Constituent lipids of lipid nanoparticles> SM-102 was manufactured by Cayman Chemical, ALC-0315 was manufactured by Ambeed, DLin-MC3-DMA (MC3) was manufactured by Selleck Biotech, and cholesterol (Chol) was manufactured by SIGMA Aldrich. 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and methoxyethylene glycol 2000-modified 2-dimyristoyl-rac-glycerol (PEG-DMG) were manufactured by NOF Corporation.

[0142] <mRNA> Of the nucleic acids to be encapsulated in the lipid nanoparticles, mRNA encoding firefly luciferase (Fluc) (CleanCap FLuc mRNA, 5 moU), mRNA encoding green fluorescent protein EGFP (EGFP mRNA, 5 moU), and mRNA encoding human erythropoietin hEPO (hEPO mRNA, 5 moU) were all manufactured by TriLink Biotechnologies.

[0143] <Preparation of lipid nanoparticles> In the following experiments, unless otherwise specified, lipid nanoparticles were prepared by the alcohol dilution method using a microchannel iLiNP (manufactured by Lilac Pharma) equipped with a built-in baffle mixer.

[0144] Specifically, first, 13.75 μL of 1 mg / mL mRNA solution was diluted with 50 mM citrate buffer (pH 4.0) to 250 μL as an RNA solution, and dispensed into a 1 mL syringe (HAMILTON). In addition, in the case of pH-responsive cationic lipid / chol / DSPC / PEG-DSG = 50 / 35 / 15 / 1.5 (mol%), 10 mM pH-responsive cationic lipid / ethanol solution 200 μL, 10 mM cholesterol / ethanol solution 140 μL, 10 mM DSPC / ethanol solution 60 μL, 1 mM PEG-DSG / ethanol solution 60 μL, and ethanol 40 μL were mixed to a total volume of 500 μL (final lipid concentration 8 mM, 100% ethanol) as a lipid solution, and dispensed into a 1 mL syringe (HAMILTON). Each syringe was attached to a syringe pump, and the pump was connected to a microchannel with a built-in baffle mixer. The RNA solution and lipid solution were pumped into the microchannel at a flow rate ratio of 3:1 (N / P = 9.3) and a total flow rate of 500 μL / min. The lipid nanoparticle solution discharged from the channel was collected. The lipid nanoparticle solution was placed in a dialysis membrane (MWCO 12,000-14,000, Spectrum Laboratories) and dialyzed against PBS(-) (pH 7.4) as the external aqueous phase at 4°C for at least 2 hours to remove ethanol and exchange the buffer. The lipid nanoparticle solution was then collected from the dialysis membrane.

[0145] <Measurement of average particle size and zeta potential of lipid nanoparticles> The average particle size (number average value), ζ-average particle size, and polydispersity index (PdI) of the lipid nanoparticles in PBS(-) (pH 7.4), as well as the zeta potential in 10 mM HEPES buffer (pH 7.4), were measured using a dynamic light scattering analyzer, Zetasizer Nano ZS ZEN3600 (manufactured by Malvern).

[0146] <Encapsulation rate of lipid nanoparticles (encapsulation efficiency)> The encapsulation rate of lipid nanoparticles was determined by measuring the amount of encapsulated nucleic acid (mRNA) using Ribogreen (Life Technologies), an RNA intercalator. The amount of mRNA was quantified based on a calibration curve created from a dilution series of mRNA solutions with known concentrations.

[0147] Specifically, 10 mM HEPES buffer (pH 7.4), 10 w / v% Triton X-100, and Ribogreen were mixed at 978.8 μL, 20 μL, and 1.25 μL per 10 wells to form the Triton(+) buffer, while 10 mM HEPES buffer (pH 7.4) was used instead of Triton X-100 to form the Triton(-) buffer. The sample was added to a black 96-well plate for fluorescence measurement at 100 μL / well, followed by the addition of 100 μL / well of either the Triton(+) buffer or the Triton(-) buffer. The plate was gently shaken (700 rpm, 30 seconds) in a shaking incubator (SI-300, AS ONE), and the fluorescence intensity of each well was measured (wavelength Ex / Em = 500 nm / 525 nm) using a μ-plate reader (VARIOSKAN LUX, Thermo Fisher Scientific) to calculate the nucleic acid encapsulation rate (%).

[0148] <Measurement of apparent pKa of lipid nanoparticles> The apparent pKa of lipid nanoparticles was measured using p-Toluenesulfonic acid (TNS). First, TNS (final concentration: 0.75 μM) and lipid nanoparticles (final concentration: 30 μM) were mixed in 200 mL of buffer solution adjusted to various pHs (pH 3.5-9.5). The buffer solution used was 20 mM citrate buffer, 20 mM sodium phosphate buffer, or 20 mM Tris-HCl buffer containing 130 mM NaCl. The fluorescence intensity of the prepared mixture was measured using a spectrofluorometer (VarioskanLux, Thermo Fisher Scientific) at λex = 321 nm and λem = 447 nm. The highest and lowest values ​​of the measured values ​​were defined as 100% and 0% charge rate, respectively, and the pH showing a 50% charge rate was calculated as the apparent pKa. The percentage of cationically charged pH-sensitive cationic lipids was calculated using the Henderson-Hasselbalch equation.

[0149] <Administration of lipid nanoparticles to mice> Lipid nanoparticles were administered to mice via the tail vein using a 27 G injection needle. Unless otherwise specified, BALB / c mice (4-5 weeks old, female) were used.

[0150] <Measurement of Fluc Activity> First, BALB / c mice (female, 4 weeks old) were intravenously injected with lipid nanoparticles encapsulating Fluc mRNA (Fluc mRNA-loaded lipid nanoparticles) at a dose of 0.1 mg mRNA / kg. Six, 24, or 48 hours after intravenous injection, the mice were euthanized, and tissues were collected, frozen in liquid nitrogen, and stored at -80°C. Tissues were homogenized in passive lysis buffer (Promega) using a bead-type cell disrupter (Micro Smash MS-100R, TOMY Seiko). Tissue debris was removed by centrifugation, and the supernatant was collected. Fluc activity in the supernatant was measured using a luciferase assay system (E1500, Promega) according to the manufacturer's protocol. Luminescence was measured using a luminometer (Luminescencer-PSN, ATTO). Protein concentration was determined using a commercially available assay kit (BCA Protein Assay Kit, Pierce). Fluc activity was expressed as relative light units (RLU) per mg of protein.

[0151] Example 1 2-(((4-(didecylamino)-4-oxobutanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(4-(didecylamino)-4-oxobutanoate) (TxT-5-4A20) was synthesized.

[0152] (1) Synthesis of 4-(didecylamino)-4-oxobutanoic acid (4A20)

[0153]

[0154] Succinic anhydride (500.4 mg, 5 mmol) dissolved in anhydrous DCM (10 mL) was added dropwise to a solution of didecylamine (1.49 mg, 5 mmol) dissolved in anhydrous DCM (10 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at 40° C. and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (4A20) (1.97 g, 99.0% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0155] (2) Synthesis of N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-3-(piperidin-1-yl)propanamide (TxT-5 head)

[0156]

[0157] Piperidine (1.98 mL, 20.0 mmol) was added to N-[tris(hydroxymethyl)methyl]acrylamide (93%, 1.884 g, 10.0 mmol) dissolved in methanol (10 mL). The resulting reaction mixture was stirred at 40 °C overnight. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of DCM and methanol. This afforded TxT-5 head (2.01 g, 81% yield) as a white powder.

[0158] (3) Synthesis of TxT-5-4A20

[0159]

[0160] Compound (4A20) (656.1 mg, 1.65 mmol) was dissolved in anhydrous DCM (2.5 mL), and TxT-5 head (130.2 mg, 0.5 mmol), DMAP (6.11 mg, 0.05 mmol), and EDCI-HCl (335.5 mg, 1.75 mmol) were added to the resulting solution. The resulting reaction mixture was stirred at 40 °C overnight and then suspended in EtOAc. The resulting suspension was washed with 0.5 N aqueous NaOH, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of 0.5% TEA in hexane and 0.5% TEA in EtOAc. This gave compound (TxT-5-4A20) (634.1 mg, 79.5% yield) as a yellow oil.

[0161] Example 2 2-(((5-(dibutylamino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(dibutylamino)-5-oxopentanoate) (TxT-5-5A8) was synthesized.

[0162] (1) Synthesis of 5-(dibutylamino)-5-oxopentanoic acid (5A8)

[0163]

[0164] Glutaric anhydride (570.5 mg, 5 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of dibutylamine (851 μL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A8) (1.21 g, 99.8% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0165] (2) Synthesis of TxT-5-5A8

[0166]

[0167] Compound (5A8) (335.5 mg, 1.65 mmol) was dissolved in anhydrous DCM (2.5 mL), and TxT-5 head (130.2 mg, 0.5 mmol), DMAP (6.11 mg, 0.05 mmol), and EDCI-HCl (335.5 mg, 1.75 mmol) were added to the resulting solution. The resulting reaction mixture was stirred at 40 °C overnight and then suspended in EtOAc. The resulting suspension was washed with 0.5 N aqueous NaOH, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of 0.5% TEA in hexane and 0.5% TEA in EtOAc. The residue was then loaded onto a reverse-phase column (Sfaer C18, Biotage) and purified by flash chromatography using a gradient mobile phase of 0.1% TFA in water and 0.1% TFA in acetonitrile / 2-propanol (1:1 (volume ratio)) to give compound (TxT-5-5A8) (321.5 mg, yield 68.7%) as a yellow oil.

[0168] Example 3 2-(((5-((2-ethylhexyl)amino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-((2-ethylhexyl)amino)-5-oxopentanoate) (TxT-5-5A8β) was synthesized.

[0169] (1) Synthesis of 5-((2-ethylhexyl)amino)-5-oxopentanoic acid (5A8β)

[0170]

[0171] Glutaric anhydride (570.5 mg, 5 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of 2-ethylhexylamine (818.7 μL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A8β) (1.22 g, 100.7% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0172] (2) Synthesis of TxT-5-5A8β

[0173]

[0174] Compound (TxT-5-5A8β) (157.9 mg, yield 33.7%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A8β) (335.5 mg, 1.65 mmol) was used instead of compound (4A20).

[0175] Example 4 2-(((5-(dipentylamino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(dipentylamino)-5-oxopentanoate) (TxT-5-5A10) was synthesized.

[0176] (1) Synthesis of 5-(dipentylamino)-5-oxopentanoic acid (5A10)

[0177]

[0178] Glutaric anhydride (570.5 mg, 5 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of diamylamine (1.01 mL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A10) (1.38 g, 102% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0179] (2) Synthesis of TXT-5-5A10

[0180]

[0181] Compound (TxT-5-5A10) (194.5 mg, yield 38.1%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the reaction mixture in the same manner as in the synthesis of compound (TxT-5-5A8), except that compound (5A10) (447.8 mg, 1.65 mmol) was used instead of compound (5A8).

[0182] Example 5 2-(((5-(dihexylamino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(dihexylamino)-5-oxopentanoate) (TxT-5-5A12) was synthesized.

[0183] (1) Synthesis of 5-(dihexylamino)-5-oxopentanoic acid (5A12)

[0184]

[0185] Glutaric anhydride (570.5 mg, 5 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of dihexylamine (1.17 mL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A12) (1.55 g, 103.5% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0186] (2) Synthesis of TxT-5-5A12

[0187]

[0188] Compound (TxT-5-5A12) (343.4 mg, yield 62.2%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A12) (494.1 mg, 1.65 mmol) was used instead of compound (4A20).

[0189] Example 6 2-(((5-(diheptylamino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(diheptylamino)-5-oxopentanoate) (TxT-5-5A14) was synthesized.

[0190] (1) Synthesis of 5-(diheptylamino)-5-oxopentanoic acid (5A14)

[0191]

[0192] Glutaric anhydride (570.5 mg, 5 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of diheptylamine (1.35 mL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A14) (1.70 g, 104% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0193] (2) Synthesis of compound (TxT-5-5A14)

[0194]

[0195] Compound (TxT-5-5A14) (393.0 mg, yield 66.1%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A14) (517.2 mg, 1.65 mmol) was used instead of compound (4A20).

[0196] Example 7 2-(((5-(dioctylamino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(dioctylamino)-5-oxopentanoate) (TxT-5-5A16) was synthesized.

[0197] (1) Synthesis of 5-(dioctylamino)-5-oxopentanoic acid (5A16)

[0198]

[0199] Glutaric anhydride (570.5 mg, 5 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of di-n-octylamine (1.51 mL, 5 mmol) in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A16) (2.05 g, 115.2% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0200] (2) Synthesis of compound (TxT-5-5A16)

[0201]

[0202] Compound (TxT-5-5A16) (527.5 mg, yield 75.4%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-5A8), except that compound (5A16) (586.7 mg, 1.65 mmol) was used instead of compound (5A8).

[0203] Example 8 2-(6-(bis(2-ethylhexyl)amino)-2,6-dioxohexyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(bis(2-ethylhexyl)amino)-5-oxopentanoate) (TxT-5-5A16b) was synthesized.

[0204] (1) Synthesis of 5-(bis(2-ethylhexyl)amino)-5-oxopentanoic acid (5A16b)

[0205]

[0206] Glutaric anhydride (600.6 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of di(2-ethylhexyl)amine (1.51 mL, 5 mmol) in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A16b) (1.76 g, 99.1% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0207] (2) Synthesis of compound (TxT-5-5A16b)

[0208]

[0209] Compound (TxT-5-5A16b) (455.0 mg, yield 72.4%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A16b) (586.7 mg, 1.65 mmol) was used instead of compound (4A20).

[0210] Example 9 2-(((5-((2-hexyldecyl)amino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-((2-hexyldecyl)amino)-5-oxopentanoate) (TxT-5-5A16β) was synthesized.

[0211] (1) Synthesis of 5-((2-hexyldecyl)amino)-5-oxopentanoic acid (5A16β)

[0212]

[0213] Glutaric anhydride (239.6 mg, 2.1 mmol) dissolved in anhydrous DCM (3 mL) was added dropwise to a solution of 2-hexyldecan-1-amine (588.9 μL, 2 mmol) dissolved in anhydrous DCM (9 mL) containing pyridine (242.1 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A16β) (728.5 mg, 41.5% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0214] (2) Synthesis of compound (TxT-5-5A16β)

[0215]

[0216] Compound (5A16β) (352.0 mg, 0.99 mmol) was dissolved in anhydrous DCM (2.5 mL), and TxT-5 head (78.1 mg, 0.3 mmol), DMAP (3.67 mg, 0.03 mmol), and EDCI-HCl (201.3 mg, 1.05 mmol) were added to the resulting solution. The resulting reaction mixture was stirred at 40 °C overnight and then suspended in EtOAc. The resulting suspension was washed with 0.5 N aqueous NaOH, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of 0.5% TEA in hexane and 0.5% TEA in EtOAc. This gave compound (TxT-5-5A16β) (281.2 mg, 73.6% yield) as a yellow oil.

[0217] Example 10 2-(6-(didecylamino)-2,6-dioxohexyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(didecylamino)-5-oxopentanoate) (TxT-5-5A20) was synthesized.

[0218] (1) Synthesis of 5-(didecylamino)-5-oxopentanoic acid (5A20)

[0219]

[0220] Glutaric anhydride (570.5 mg, 5 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of didecylamine (1.49 mg, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A20) (1.98 g, 96.1% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0221] (2) Synthesis of compound (TxT-5-5A20)

[0222]

[0223] Compound (TxT-5-5A20) (448.6 mg, yield 62.9%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A20) (679.3 mg, 1.65 mmol) was used instead of compound (4A20).

[0224] Example 11 2-(6-(didodecylamino)-2,6-dioxohexyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(didodecylamino)-5-oxopentanoate) (TxT-5-5A24) was synthesized.

[0225] (1) Synthesis of 5-(didodecylamino)-5-oxopentanoic acid (5A24)

[0226]

[0227] Glutaric anhydride (600.6 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of didodecylamine (1.77 g, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A24) (2.26 g, 96.5% yield) as a colorless oil. The crude product was used in the next reaction without further purification.

[0228] (2) Synthesis of compound (TxT-5-5A24)

[0229]

[0230] Compound (TxT-5-5A24) (634.1 mg, yield 79.5%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A24) (771.8 mg, 1.65 mmol) was used instead of compound (4A20).

[0231] Example 12 Bis(2-hexyloctyl)O,O'-(2-(((5-((2-hexyloctyl)oxy)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl)diglutarate (TxT-5-5E14) was synthesized.

[0232] (1) Synthesis of 5-((2-hexyl)oxy)-5-oxopentanoic acid (5E14)

[0233]

[0234] Glutaric anhydride (600.6 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of 2-hexyl-1-n-octanol (1.29 mL, 5 mmol) dissolved in a mixture of TEA (1.29 mL) and anhydrous DCM (15 mL). The reaction mixture was stirred at 40°C overnight and then evaporated. The resulting residue was suspended in EtOAc, washed with 1N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5E14) (1.71 g, 104.3% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0235] (2) Synthesis of compound (TxT-5-5E14)

[0236]

[0237] Compound (5E14) (599.5 mg, 1.83 mmol) was dissolved in anhydrous DCM (3.0 mL), and TxT-5 head (130.2 mg, 0.5 mmol), DMAP (6.72 mg, 0.055 mmol), and EDCI-HCl (359.0 mg, 1.93 mmol) were added to the resulting solution. The resulting reaction mixture was stirred at 40 °C overnight and then suspended in EtOAc. The resulting suspension was washed with 0.5 N aqueous NaOH, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of 0.5% TEA in hexane and 0.5% TEA in EtOAc. This gave compound (TxT-5-5E14) (411.5 mg, 69.1% yield) as a yellow oil.

[0238] Example 13 Bis(2-butyloctyl)O,O'-(2-(((5-((2-butyloctyl)oxy)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl)diglutarate (TxT-5-5E12) was synthesized.

[0239] (1) Synthesis of 5-((2-butyloctyl)oxy)-5-oxopentanoic acid (5E12)

[0240]

[0241] Glutaric anhydride (600.6 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of 2-butyl-1-n-octanol (1.15 mL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing TEA (1.04 mL). The reaction mixture was stirred overnight at 40 °C and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous Na2SO4. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5E12) (1.65 g, 109.7% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0242] (2) Synthesis of Compound (TxT-5-5E12)

[0243]

[0244] The compound (TxT-5-5E12) is obtained as a yellow oil by reacting with TxT-5 head and purifying it in the same manner as in the synthesis of compound (TxT-5-5E14), except that compound (5E12) is used instead of compound (5E14).

[0245] Example 14 2-(((5-((2-butyloctyl)amino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-((2-butyloctyl)amino)-5-oxopentanoate) (TxT-5-5A12β) was synthesized.

[0246] (1) Synthesis of 5-((2-butyloctyl)amino)-5-oxopentanoic acid (5A12β)

[0247]

[0248] Glutaric anhydride (300.3 mg, 2.63 mmol) dissolved in anhydrous DCM (7.5 mL) was added dropwise to a solution of 2-butyl-n-octan-1-amine (579 μL, 2.5 mmol) in anhydrous DCM (2.5 mL) containing TEA (522 μL, 3.75 mmol). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A12β) (764.4 mg, 102% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0249] (2) Synthesis of Compound (TxT-5-5A12β)

[0250]

[0251] Compound (5A12β) (324.2 mg, 0.99 mmol) was used instead of compound (5A16β), and further, as the gradient mobile phase for flash chromatography, hexane and 0.5% TEA-containing EtOAc were used instead of 0.5% TEA-containing hexane and 0.5% TEA-containing EtOAc. The resulting product was reacted with the TxT-5 head and purified in the same manner as in the synthesis of compound (TxT-5-5A16β), to obtain compound (TxT-5-5A12β (223.6 mg, yield 62.7%)) as a yellow oil.

[0252] Example 15 2-(((5-((2-hexyloctyl)amino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-((2-hexyloctyl)amino)-5-oxopentanoate) (TxT-5-5A14β) was synthesized.

[0253] (1) Synthesis of 2-hexyloctyl methanesulfonate

[0254]

[0255] 2-Hexyl-1-octanol (2.58 mL, 10 mmol) suspended in anhydrous DCM (20 mL) was added to methanesulfonyl chloride (854.2 μL, 11 mmol) and TEA (1.67 mL) and stirred at room temperature for 16 hours. The resulting reaction mixture was evaporated, and the resulting residue was suspended in EtOAc. This suspension was washed with neutral water and brine and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave 2-hexyloctyl methanesulfonate (2.58 g, 90% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0256] (2) Synthesis of 2-hexyloctan-1-amine

[0257]

[0258] 2-Hexyloctyl methanesulfonate (1.32 g, 4.5 mmol) was dissolved in 7N NH3 in methanol (64.3 mL, 450 mmol) and stirred at 40 °C for 2 weeks. The resulting reaction mixture was bubbled with argon gas. The reaction mixture was evaporated, and the resulting residue was suspended in DCM. The resulting suspension was washed with 1N aqueous HCl, water, and brine, and dried over anhydrous Na2SO4. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of DCM and methanol. This afforded 2-hexyloctan-1-amine (426.7 mg, 44.4% yield) as a yellow oil.

[0259] (3) Synthesis of 5-((2-hexyloctyl)amino)-5-oxopentanoic acid (5A14β)

[0260]

[0261] Glutaric anhydride (239.6 mg, 2.1 mmol) dissolved in anhydrous DCM (3 mL) was added dropwise to a solution of 2-hexyloctan-1-amine (426.8 mg, 2 mmol) dissolved in anhydrous DCM (7 mL) containing pyridine (242.1 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A14β) (617.8 mg, 94.3% yield) as a yellow solid. The crude product was used in the next reaction without further purification.

[0262] (4) Synthesis of compound (TxT-5-5A14β)

[0263]

[0264] Compound (TxT-5-5A14β) (211.7 mg, yield 35.6%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A14β) (540.4 mg, 1.65 mmol) was used instead of compound (4A20).

[0265] Example 16 2-(((5-((2-decyltetradecyl)amino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-((2-decyltetradecyl)amino)-5-oxopentanoate) (TxT-5-5A24β) was synthesized.

[0266] (1) Synthesis of 5-((2-decyltetradecyl)amino)-5-oxopentanoic acid (5A24β)

[0267]

[0268] Glutaric anhydride (299.5 mg, 2.63 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of 2-decyltetradecan-1-amine (884 mg, 2.5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (302.7 μL). The reaction mixture was stirred overnight at ambient temperature and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A24β) (1.05 g, 89.9% yield) as a yellow oil. The crude product was used in the next reaction without further purification.

[0269] (2) Synthesis of Compound (TxT-5-5A24β)

[0270]

[0271] Compound (TxT-5-5A24β) (548.2 mg, yield 68.1%) was obtained as a yellow oil by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4A20), except that compound (5A24β) (884 mg, 1.65 mmol) was used instead of compound (4A20).

[0272] Example 17 2-((2-(2-((diheptylamino)methyl)cyclohexyl)acetoxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(2-(diheptylcarbamoyl)cyclohexane-1-carboxylate) (TxT-5-4(6)A14) was synthesized.

[0273] (1) Synthesis of 2-(diheptylcarbamoyl)cyclohexane-1-carboxylic acid (4(6)A14)

[0274]

[0275] (±)-trans-1,2-Cyclohexanedicarboxylic anhydride (809.4 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of diheptylamine (1.35 mL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at 40°C and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This gave compound 4(6)A14 (1.93 g, 104.9% yield) as a colorless oil. The crude product was used in the next reaction without further purification.

[0276] (2) Synthesis of Compound (TxT-5-4(6)A14)

[0277]

[0278] Compound (4(6)A14) (599.5 mg, 1.83 mmol) was dissolved in anhydrous DCM (2.5 mL), and TxT-5 head (130.2 mg, 0.5 mmol), DMAP (6.11 mg, 0.05 mmol), and EDCI-HCl (335.5 mg, 1.75 mmol) were added to the resulting solution. The resulting reaction mixture was stirred at 40 °C overnight and then suspended in EtOAc. The resulting suspension was washed with 0.5 N aqueous NaOH, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of hexane and EtOAc. This gave compound (TxT-5-4(6)A14) (293.5 mg, 44.8% yield) as a colorless oil.

[0279] Example 18 2-(((5-(decylamino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(decylamino)-5-oxopentanoate) (TxT-5-5A10L) was synthesized.

[0280] (1) Synthesis of 5-(decylamino)-5-oxopentanoic acid (5A10L)

[0281]

[0282] Glutaric anhydride (600.6 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of 1-aminodecane (983.1 mL, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at 40° C. and then evaporated. The resulting residue was suspended in EtOAc, washed with 1 N aqueous HCl, water, and brine, and dried over anhydrous Na2SO4. The resulting solution was filtered, and the filtrate was evaporated. This gave compound (5A10L) (1.17 g, 86.2% yield) as a white powder. The crude product was used in the next reaction without further purification.

[0283] (2) Synthesis of compound (TxT-5-5A10L)

[0284]

[0285] Compound (TxT-5-5A10L) (410.6 mg, yield 80.5%) was obtained as a white solid by reacting with TxT-5 head and purifying the product in the same manner as in the synthesis of compound (TxT-5-4(6)A14), except that compound (5A10L) (447.8 mg, 1.65 mmol) was used instead of compound (4(6)A14).

[0286] Example 19 2-(((5-(dodecylamino)-5-oxopentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-(dodecylamino)-5-oxopentanoate) (TxT-5-5A12L) was synthesized.

[0287] (1) Synthesis of 5-(dodecylamino)-5-oxopentanoic acid (5A12L)

[0288]

[0289] Glutaric anhydride (600.6 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of dodecylamine (926.8 mg, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at 40° C. and then evaporated. The resulting residue was suspended in EtOAc, washed with 1N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A12L) (968.1 mg, 64.7% yield) as a white powder. The crude product was used in the next reaction without further purification.

[0290] (2) Synthesis of compound (TxT-5-5A12L)

[0291]

[0292] Compound (TxT-5-5A12L) (220.1 mg, yield 39.8%) was obtained as a white powder by reacting with TxT-5 head and purifying in the same manner as in the synthesis of compound (TxT-5-4(6)A14), except that compound (5A12L) (494.1 mg, 1.65 mmol) was used instead of compound (4(6)A14).

[0293] Example 20 2-(((5-oxo-5-(tetradecylamino)pentanoyl)oxy)methyl)-2-(3-(piperidin-1-yl)propanamido)propane-1,3-diyl bis(5-oxo-5-(tetradecylamino)pentanoate) (TxT-5-5A14L) was synthesized.

[0294] (1) Synthesis of 5-oxo-5-(dodecylamino)pentanoic acid (5A14L)

[0295]

[0296] Glutaric anhydride (600.6 mg, 5.25 mmol) dissolved in anhydrous DCM (5 mL) was added dropwise to a solution of tetradecylamine (1.07 g, 5 mmol) dissolved in anhydrous DCM (15 mL) containing pyridine (605.4 μL). The reaction mixture was stirred overnight at 40° C. and then evaporated. The resulting residue was suspended in EtOAc, washed with 1N aqueous HCl, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. This afforded compound (5A14L) (337.2 mg, 20.6% yield) as a white powder. The crude product was used in the next reaction without further purification.

[0297] (2) Synthesis of compound (TxT-5-5A14L)

[0298]

[0299] Compound (5A14L) (270.2 mg, 0.825 mmol) was dissolved in anhydrous DCM (2.5 mL), and TxT-5 head (65.1 mg, 0.25 mmol), DMAP (3.05 mg, 0.025 mmol), and EDCI-HCl (167.74 mg, 0.875 mmol) were added to the resulting solution. The resulting reaction mixture was stirred at 40 °C overnight and then suspended in EtOAc. The resulting suspension was washed with 0.5 N aqueous NaOH, water, and brine, and dried over anhydrous NaSO. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Silica HCD, Biotage) and purified by flash chromatography using a gradient mobile phase of hexane and EtOAc. This gave the compound (TxT-5-5A14L) (97.2 mg, yield 32.6%) as a white powder.

[0300] Example 21 2-(((5-(diheptylamino)-5-oxopentanoyl)oxy)methyl)-2-(1-isopropylpiperidine-4-carboxamido)propane-1,3-diyl bis(5-(diheptylamino)-5-oxopentanoate) (TxT-19-5A14) was synthesized.

[0301] (1) Synthesis of N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-1-isopropylpiperidine-4-carboxamide (TxT-19 head)

[0302]

[0303] Ethyl chloroformate (434.0 mg, 4.0 mmol) was added dropwise to 1-(propan-2-yl)piperidine-4-carboxylic acid hydrochloride (747.7 mg, 3.6 mmol) and TEA (809.5 mg, 8.0 mmol) in THF (10 mL) at 0 °C under an argon atmosphere, and the mixture was stirred at 0 °C for 30 min. The resulting reaction mixture was added to DMF (10 mL) containing tris(hydroxymethyl)aminomethane (436.1 mg, 3.6 mmol) and stirred at 60 °C overnight. The reaction was monitored by TLC, and TEA (809.5 mg, 8.0 mmol) was added to the resulting reaction mixture. The solid was filtered, and the DMF and THF were evaporated in vacuo. The resulting residue was loaded onto a normal-phase column (Sfaer Amino D, Biotage) and purified by flash chromatography using a gradient mobile phase of DCM and methanol. This gave TxT-19 head (508.2 mg, 51.4% yield) as a yellow powder.

[0304] (2) Synthesis of TxT-19-5A14

[0305]

[0306] Compound (5A14) (310.3 mg, 0.95 mmol) was dissolved in anhydrous DCM (1.5 mL), and the resulting solution was added with TxT-19 head (82.3 mg, 0.3 mmol), DMAP (3.70 mg, 0.03 mmol), and EDCI-HCl (201.3 mg, 1.05 mmol). The resulting reaction mixture was stirred overnight at 40 °C under an argon atmosphere. After concentration in vacuo, the resulting mixture was diluted with 20% aqueous methanol and extracted with hexane. The aqueous layer was made alkaline with Na2CO3, and the organic layer was washed with 20% aqueous methanol and dried over anhydrous Na2SO4. The resulting solution was filtered, and the filtrate was evaporated. The residue was loaded onto a normal-phase column (Sfaer Amino D, Biotage) and purified by flash chromatography using a gradient mobile phase of hexane and EtOAc. This gave compound (TxT-19-5A14) (106.3 mg, 29.3% yield) as a viscous yellow oil.

[0307] [Example 22] Lipid nanoparticles were prepared using TxT lipids TxT-5-5A8, TxT-5-5A8β, TxT-5-5A10, TxT-5-5A12, TxT-5-5A12β, TxT-5-5A14, and TxT-5-5A16 as constituent lipids. Phosphatidylcholine (PC), cholesterol, and PEG-DMG were used as lipids other than the TxT lipids. DSPC was used as the PC.

[0308] Specifically, lipid nanoparticles loaded with Fluc mRNA (Fluc mRNA-loaded lipid nanoparticles) were prepared by the alcohol dilution method using TxT, DSPC, cholesterol, and PEG-DMG in a composition of TxT / DSPC / chol / PEG-DMG = 50 / 15 / 35 / 1.5 (mol%). The ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), mRNA concentration (μg / μL), and pKa of each Flu mRNA-loaded lipid nanoparticle are shown in Table 1. In Table 1, "nd" means not determined.

[0309]

[0310] As shown in Table 1, lipid nanoparticles encapsulating mRNA could be produced using any of the TxT lipids. Furthermore, the physical properties of these lipid nanoparticles were such that they could be used as gene carriers.

[0311] Next, mice were administered Flu c mRNA-loaded lipid nanoparticles prepared using TxT-5-5A10, TxT-5-5A12, TxT-5-5A12β, TxT-5-5A14, and TxT-5-5A16, and luciferase expression levels (Fluc activity) in each tissue were examined. Specifically, each Flu c mRNA-loaded lipid nanoparticle was administered to Balb / c mice at a dose of 0.1 mg mRNA / kg. Six hours after administration, the mice were euthanized, and each organ was collected and Flu c activity (RLU / mg protein) was measured (N=2 or 4). The results are shown in Figure 1.

[0312] As shown in Figure 1, in mice administered with either lipid nanoparticle, Fluc activity was confirmed in the liver, spleen, kidney, lung, heart, brain, and muscle. These results confirmed that lipid nanoparticles containing TxT lipids are useful as gene carriers targeting various organs. Furthermore, these Fluc mRNA-loaded lipid nanoparticles were confirmed to have high Fluc activity, particularly in the liver and spleen. In particular, lipid nanoparticles containing TxT-5-5A12 and TxT-5-5A12β as constituent lipids had the highest Fluc activity in the spleen, making them promising carriers targeting the spleen.

[0313] Example 23 Using TxT-5-5A16, which had the highest Fluc activity in the liver in Example 22, lipid nanoparticles with varying DSPC content were prepared, and the luciferase expression level (Fluc activity) in each tissue was examined.

[0314] Specifically, Fluc mRNA-loaded lipid nanoparticles were prepared in the same manner as in Example 22, using TxT-5-5A16, DSPC, cholesterol, and PEG-DMG in a composition of TxT-5-5A16 / DSPC / chol / PEG-DMG=50 / X / 50-X / 1.5 (mol%) (X=3, 6, 9, 12, or 15). The ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), mRNA concentration (μg / μL), and pKa of each Fluc mRNA-loaded lipid nanoparticle are shown in Table 2.

[0315]

[0316] Next, mice were administered each Fluc mRNA-loaded lipid nanoparticle, and luciferase expression levels (Fluc activity) in each tissue were examined (N=2) in the same manner as in Example 22. The results are shown in Figures 2A-E. In the figures, "3%, "6%, "9%, and "15%" indicate the results for mice administered Fluc mRNA-loaded lipid nanoparticles with DSPC contents of 3 mol%, 6 mol%, 9 mol%, and 15 mol%, respectively. No effect of DSPC content on the intensity of Fluc activity was observed in the spleen (Figure 2B), kidney (Figure 2C), lung (Figure 2D), and heart (Figure 2E). In the liver (Figure 2A), the lower the DSPC content, the stronger the Fluc activity. Compared to lipid nanoparticles with 15 mol% DSPC, lipid nanoparticles with 3 mol% DSPC were approximately 10 times more active.

[0317] [Example 24] Lipid nanoparticles containing 3 mol% DSPC were prepared using TxT lipids such as TxT-5-5A12, TxT-5-5A12β, TxT-5-5A14, TxT-5-5A16, TxT-5-5A16b, TxT-5-5A16β, TxT-5-5A20, TxT-5-5A24, TxT-5-5E14, and TxT-5-4A20 as constituent lipids.

[0318] Specifically, Fluc mRNA-loaded lipid nanoparticles were prepared by the alcohol dilution method using TxT, DSPC, cholesterol, and PEG-DMG in a composition of TxT / DSPC / chol / PEG-DMG = 50 / 3 / 47 / 1.5 (mol%). Table 3 shows the ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), mRNA concentration (μg / μL), and pKa of each Fluc mRNA-loaded lipid nanoparticle.

[0319]

[0320] Next, as in Example 22, each Fluc mRNA-loaded lipid nanoparticle was administered to mice, and the luciferase expression level (Fluc activity) in each tissue was examined (N = 2 or 8). The results are shown in Figures 3A to 3E. In mice administered with either lipid nanoparticle, Fluc activity was observed in the liver (Figure 3A) at least 10 times higher than in the spleen (Figure 3B), kidney (Figure 3C), lung (Figure 3D), and heart (Figure 3E). In particular, the highest Fluc activity was observed in mice administered lipid nanoparticles containing TxT-5-5A14 as a constituent lipid, suggesting that lipid nanoparticles containing TxT-5-5A14 as a constituent lipid are promising carriers targeting the liver.

[0321] [Example 25] The liver uptake efficiency of lipid nanoparticles containing TxT-5-5A14 as a constituent lipid was compared with that of Fluc mRNA-loaded lipid nanoparticles using SM-102, ALC-0315, or MC3 as a cationic lipid.

[0322] Specifically, Fluc mRNA-loaded lipid nanoparticles were prepared by the alcohol dilution method using TxT-5-5A14, DSPC, cholesterol, and PEG-DMG in a composition of TxT-5-5A14 / DSPC / chol / PEG-DMG = 50 / 3 / 47 / 1.5 (mol%). Furthermore, when SM-102, ALC-0315, or MC3 was used as the cationic lipid, Fluc mRNA-loaded lipid nanoparticles were prepared by the alcohol dilution method in a composition of cationic lipid / DSPC / chol / PEG-DMG = 50 / 10 / 40 / 1.5 (mol%). The ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), mRNA concentration (μg / μL), and pKa of each Fluc mRNA-loaded lipid nanoparticle are shown in Table 4.

[0323]

[0324] Next, as in Example 22, each Fluc mRNA-loaded lipid nanoparticle was administered to mice, and the amount of luciferase expression (Fluc activity) in the liver was examined (N=3). The results are shown in Figure 4. Mice administered with lipid nanoparticles containing TxT-5-5A14 as the constituent lipid exhibited significantly higher Fluc activity than mice administered with lipid nanoparticles containing other cationic lipids, suggesting that lipid nanoparticles containing TxT-5-5A14 as the constituent lipid may be a superior gene carrier to existing gene carriers.

[0325] [Example 26] The uptake of lipid nanoparticles containing TxT-5-5A14 as a constituent lipid into various liver cells was compared with that of Fluc mRNA-loaded lipid nanoparticles using SM-102, ALC-0315, or MC3 as a cationic lipid.

[0326] Specifically, first, EGFP mRNA-loaded lipid nanoparticles having a composition of TxT-5-5A14 / DSPC / chol / PEG-DMG=50 / 3 / 47 / 1.5 (mol%) and EGFP mRNA-loaded lipid nanoparticles having a composition of SM-102, ALC-0315, or MC3 / DSPC / chol / PEG-DMG=50 / 10 / 40 / 1.5 (mol%) were prepared in the same manner as in Example 25, except that EGFP mRNA was used instead of Fluc mRNA.

[0327] Next, each EGFP mRNA-loaded lipid nanoparticle was administered to Balb / c mice at a dose of 0.2 mg mRNA / kg. 23 hours and 50 minutes after administration, fluorescently labeled lectin (DyLight-649 Lycopersicon (Tomato) Lectin) was administered at 40 μg / mouse via the tail vein to fluorescently label vascular endothelial cells. 24 hours after lipid nanoparticle administration, the mice were euthanized, the livers were collected, and tissue sections were prepared. For nuclear staining, the tissue sections were immersed in a nuclear staining solution (a solution of 1 μg / mL Hoechst 33342 dissolved in PBS(-)), cooled on ice, and incubated in the dark for 30 minutes or more. The stained tissue sections were observed using a confocal laser scanning microscope.

[0328] Microscopic images of liver tissue sections from each mouse are shown in Figure 5. In the figure, the upper row is a fluorescent image of EGFP, and the lower row is a fluorescent image of vascular endothelial cells (fluorescently labeled lectin). As shown in Figure 5, in the livers of mice administered EGFP mRNA-loaded lipid nanoparticles containing TxT-5-5A14 as a constituent lipid, GFP was expressed not only in hepatocytes but also in vascular endothelial cells. These results confirmed that lipid nanoparticles containing TxT lipids are taken up not only by hepatocytes but also by vascular endothelial cells in the liver.

[0329] [Example 27] EGFP mRNA-loaded lipid nanoparticles containing various TxT lipids were administered to mice, and the expression efficiency in liver cells was examined. The TxT lipids used were TxT-5-5A12, TxT-5-5A12β, TxT-5-5A14, TxT-5-5A16, TxT-5-5A16b, TxT-5-5A16β, TxT-5-5A20, TxT-5-5A24, TxT-5-5E14, and TxT-5-4A20.

[0330] Specifically, EGFP mRNA-loaded lipid nanoparticles having a composition of TxT / DSPC / chol / PEG-DMG=50 / 3 / 47 / 1.5 (mol%) were prepared in the same manner as in Example 24, except that EGFP mRNA was used instead of Fluc mRNA and the total flow rate during delivery into the microchannel was 3.0 mL / min. Table 5 shows the ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), and mRNA concentration (μg / μL) of each EGFP mRNA-loaded lipid nanoparticle. As shown in Table 5, uniform particles were prepared with all TxT lipids.

[0331]

[0332] Next, as in Example 26, each EGFP mRNA-loaded lipid nanoparticle was administered to Balb / c mice, and 23 hours and 50 minutes after administration, fluorescently labeled lectin was administered. 24 hours after lipid nanoparticle administration, the mice were euthanized, their livers were collected, and tissue sections were prepared. Each tissue section was observed using a confocal laser scanning microscope. Microscopic images of liver tissue sections from each mouse are shown in Figure 6. In the figure, the upper row is a fluorescent image of EGFP, and the lower row is a fluorescent image of vascular endothelial cells (fluorescently labeled lectin).

[0333] As shown in Figure 6, EGFP fluorescence was observed in the liver tissue of mice administered EGFP mRNA-loaded lipid nanoparticles containing TxT-5-5A12, TxT-5-5A12β, TxT-5-5A14, TxT-5-5A16b, TxT-5-5A16β, TxT-5-5A24, TxT-5-5E14, and TxT-5-5A20. In particular, very high gene expression was observed in the hepatocytes of mice administered EGFP mRNA-loaded lipid nanoparticles containing TxT-5-5A12β, TxT-5-5A14, and TxT-5-5A24. These results confirmed that lipid nanoparticles containing TxT lipids are useful as liver-targeted gene carriers. Furthermore, in the liver tissue of mice administered EGFP mRNA-loaded lipid nanoparticles containing TxT-5-4A20 and TxT-5-5A16, EGFP was not expressed to the extent that fluorescence was visible under these observation conditions (observation 24 hours after administration), suggesting that the time required for maximum gene expression after administration may differ depending on the TxT lipid.

[0334] Example 28 The time course of gene expression levels in the liver of lipid nanoparticles containing TxT-5-5A12β and TxT-5-5A14 as constituent lipids was evaluated.

[0335] Specifically, Fluc mRNA-loaded lipid nanoparticles were prepared by the alcohol dilution method using TxT-5-5A12β or TxT-5-5A14, DSPC, cholesterol, and PEG-DMG in a composition of TxT-5-5A12β or TxT-5-5A14 / DSPC / chol / PEG-DMG = 50 / 3 / 47 / 1.5 (mol%). Table 6 shows the ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), and mRNA concentration (μg / μL) of each Fluc mRNA-loaded lipid nanoparticle.

[0336]

[0337] Next, as in Example 22, each Fluc mRNA-loaded lipid nanoparticle was administered to mice, and the amount of luciferase expression (Fluc activity) in the liver was examined 6, 24, and 48 hours after administration (N=3). The results are shown in Figure 7. Lipid nanoparticles containing TxT-5-5A12β as a constituent lipid and lipid nanoparticles containing TxT-5-5A14 as a constituent lipid showed equivalent gene expression intensity at all times.

[0338] Example 29 The time course of hEPO expression efficiency in lipid nanoparticles containing TxT-5-5A12β and TxT-5-5A14 as constituent lipids was compared with that of hEPO mRNA-loaded lipid nanoparticles using SM-102.

[0339] Specifically, hEPO mRNA-loaded lipid nanoparticles were prepared by the alcohol dilution method using TxT-5-5A12β or TxT-5-5A14, DSPC, cholesterol, and PEG-DMG in a composition of TxT-5-5A12β or TxT-5-5A14 / DSPC / chol / PEG-DMG = 50 / 3 / 47 / 1.5 (mol%). When SM-102 was used as the cationic lipid, hEPO mRNA-loaded lipid nanoparticles were prepared by the alcohol dilution method using a composition of SM-102 / DSPC / chol / PEG-DMG = 50 / 10 / 40 / 1.5 (mol%). The ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), and mRNA concentration (μg / μL) of each hEPO mRNA-loaded lipid nanoparticle are shown in Table 7.

[0340]

[0341] Next, mice were administered each hEPO mRNA-loaded lipid nanoparticle, and blood was collected from the tail vein 6, 24, and 48 hours after administration (N=3). The blood was allowed to stand at room temperature for 90 minutes, then centrifuged at 1,000 x g for 15 minutes at 25°C. The supernatant was collected, and serum was obtained. Serum hEPO activity was measured using a commercially available ELISA kit (Human EPO ELISA Kit, Invitrogen). Standard curve samples were prepared by serial dilution from 100 mIU / mL to 50, 25, 12.5, 6.3, and 3.1 ng / mL, with 450 μL each. Serum samples were diluted 10- to 10,000-fold to fall within the standard curve range. 100 μL of the standard curve sample and serum sample were applied to a plate, and 450 μL of biotin-conjugate was added and incubated at 18-25°C for 1 hour. The wells were washed six times, and 100 μL of Streptavidin-HRP was applied to each well, followed by incubation for 15 minutes at 18-25°C. The wells were washed six times again, and 100 μL of TMB Substrate Solution was applied to each well. The plate was shielded from light with aluminum foil and incubated for 10 minutes at 18-25°C. 100 μL of Stop Solution was then applied, and the absorbance at 450 nm was measured using a spectrofluorometer (VarioskanLux, Thermo Fisher Scientific).

[0342] The results are shown in Figure 8. Both mice administered lipid nanoparticles containing TxT-5-5A12β as the constituent lipid and mice administered lipid nanoparticles containing TxT-5-5A14 as the constituent lipid showed significantly higher hEPO concentrations than mice administered lipid nanoparticles containing SM-102 as the constituent lipid, suggesting that lipid nanoparticles containing TxT-5-5A12β or TxT-5-5A14 as the constituent lipid may be superior gene carriers to existing gene carriers.

[0343] [Example 30] As the TxT lipid, TxT-5-5A12, TxT-5-5A12β, TxT-5-5A14, TxT-5-5A14β, TxT-5-5A16, TxT-5-5A16b, TxT-5-5A16β, TxT-5-5A20, TxT-5-5A24, TxT-5-5A24β, TxT-5-5E14, and TxT-5-4A20 were used as constituent lipids to prepare lipid nanoparticles containing 3 mol% DSPC (Fluc mRNA-loaded lipid nanoparticles), and the amount of luciferase expression in the liver (Fluc activity) was examined.

[0344] Each of the prepared Fluc mRNA-loaded lipid nanoparticles was tested in the same manner as in Example 24 (N = 3 to 9). The results of measuring Fluc activity (RLU / mg protein) in the livers of mice administered with Fluc mRNA-loaded lipid nanoparticles are shown in Figure 9. Fluc activity was confirmed in mice administered with any of the lipid nanoparticles.

[0345] [Example 31] Lipid nanoparticles containing 3 mol% DSPC (Fluc mRNA-loaded lipid nanoparticles) were prepared using TxT-5-4(6)A14 as the constituent lipid as the TxT lipid, and the luciferase expression level (Fluc activity) in each tissue was examined.

[0346] The prepared Fluc mRNA-loaded lipid nanoparticles were tested in the same manner as in Example 24 (except N = 3). The results of measuring Fluc activity (RLU / mg protein) in the liver, spleen, and lungs of mice administered Fluc mRNA-loaded lipid nanoparticles are shown in Figure 10. Fluc activity was observed in the liver, spleen, and lungs, with particularly high activity confirmed in the liver.

[0347] [Example 32] Lipid nanoparticles containing various TxT lipids were used as DDS carriers for genome editing. TxT-5-5A12β, TxT-5-5A14, and TxT-5-5A24, which were observed to show high gene expression in Example 27, were used as TxT lipids.

[0348] Specifically, first, an RNA solution (N / P = 6.0) was prepared containing Cas9-mRNA (TriLink, 5 moU modified) and gRNA targeting transthyretin (TTR) at a mass ratio of 1:2. Using this RNA solution, lipid nanoparticles (TTR-targeted genome editing lipid nanoparticles) with a composition of TxT / DSPC / chol / PEG-DMG = 50 / 3 / 47 / 1.5 (mol%) were prepared in the same manner as in Example 27. The ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), and mRNA concentration (μg / μL) of each TTR-targeted genome editing lipid nanoparticle are shown in Table 8.

[0349]

[0350] As shown in Table 8, uniform particles could be prepared with all TxT lipids. The lipid nanoparticles containing TxT-5-5A24 had the smallest average particle size, and the lipid nanoparticles containing TxT-5-5A12β had the largest average particle size. This indicates that the lipid with a short scaffold carbon number (R in general formula (I)) 1 Particles composed of lipids with a small number of carbon atoms (e.g., lipids with a small number of carbon atoms) tended to have a larger average particle size. Furthermore, lipid nanoparticles for TTR-targeted genome editing encapsulating Cas9 mRNA tended to have a smaller average particle size than lipid nanoparticles encapsulating Fluc mRNA (Example 24) or lipid nanoparticles encapsulating EGFP mRNA (Example 27), even when the lipid composition was the same.

[0351] Next, each of the prepared TTR-targeted genome editing lipid nanoparticles was administered (1.5 mg Cas9 mRNA / kg) via the tail vein to Balb / c mice (4-week-old females). One week after administration, the mice were euthanized and blood was collected from the inferior vena cava (N=3). The blood was left to stand at room temperature for 1 hour, then centrifuged at 25°C and 1,000 x g for 15 minutes. The supernatant was collected and serum was obtained. Serum TTR concentrations were measured using a commercially available ELISA kit (Prealbumin ELISA Kit Mouse, Aviva Systems Biology). Standard curve samples were prepared by serial dilution from 500 ng / mL to 250, 125, 62.5, 31.25, and 15.63 ng / mL, 300 μL each. For serum samples, serum was diluted 10,000-fold. 100 μL of the standard curve samples and serum samples were applied to the plate and incubated at 25°C for 30 minutes. The wells were washed four times, and 100 μL of enzyme-antibody conjugate was applied to each well. The plate was protected from light with aluminum foil and then incubated at 25°C for 20 minutes. The wells were washed four times again, and 100 μL of TMB Substrate Solution (Aviva Systems Biology) was applied to each well. The plate was protected from light with aluminum foil and then incubated at 25°C for 10 minutes. 100 μL of Stop Solution (Aviva Systems Biology) was then applied, and the absorbance at 450 nm was measured using a spectrofluorometer (VarioskanLux, Thermo Fisher Scientific).

[0352] Figure 11 shows the results of measuring the amount of TTR in serum (µg / mL) and TTR knockdown efficiency (%). In the figure, "NT" represents the measurement result of serum from mice that were not administered lipid nanoparticles. TTR-targeted genome editing lipid nanoparticles containing TxT-5-5A12β and TxT-5-5A14 showed extremely high TTR knockout activity of 85% or more. These results suggest that efficient genome editing by mRNA can be achieved by using lipid nanoparticles containing TxT-5-5A12β or TxT-5-5A14 as a constituent lipid.

[0353] [Example 33] Lipid nanoparticles containing TxT-5-5A14 as a constituent lipid were used as DDS carriers for genome editing.

[0354] Specifically, first, an RNA solution (N / P = 6.0) was prepared containing Cas9-mRNA (TriLink, 5moU modified) and highly modified gRNA (SEQ ID NO: 2) targeting transthyretin (TTR) at a mass ratio of 1:2. Using this RNA solution, lipid nanoparticles (TTR-targeted genome editing lipid nanoparticles) with a composition of TxT-5-5A14 / DSPC / chol / PEG-DMG = 50 / 3 / 47 / 1.5 (mol%) were prepared in the same manner as in Example 32. The ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), and mRNA concentration (μg / μL) of each TTR-targeted genome editing lipid nanoparticle are shown in Table 9.

[0355]

[0356] Next, lipid nanoparticles for TTR-targeted genome editing were administered to mice in the same manner as in Example 32, except that the Cas9-mRNA dose was adjusted to 0.1, 0.3, and 1.0 mg / kg, and the serum TTR levels (μg / mL) were measured (N=3). The measurement results are shown in Figure 12. In the figure, "NT" indicates the serum measurement results of mice that were not administered lipid nanoparticles. A dose-dependent increase in TTR knockout efficiency was observed, with a TTR knockout activity of 60% or more at 0.3 mg RNA / kg. These results suggest that efficient genome editing using mRNA can be achieved by using lipid nanoparticles containing TxT-5-5A14 as a constituent lipid as a carrier.

[0357] [Example 34] Lipid nanoparticles containing TxT-5-5A14 as a constituent lipid were used as DDS carriers for genome editing.

[0358] Specifically, first, an RNA solution (N / P = 6.0) was prepared using Cas9-mRNA (TriLink, 5moU modified) and gRNA (SEQ ID NO: 3) targeting proprotein convertase subtilisin / kexin type 9 (PCSK9) at a mass ratio of 1:2. Using this RNA solution, lipid nanoparticles (PCSK9-targeted genome editing lipid nanoparticles) with a composition of TxT-5-5A14 / DSPC / chol / PEG-DMG = 50 / 3 / 47 / 1.5 (mol%) were prepared in the same manner as in Example 32. The ζ-average particle size (nm), number-average particle size (nm), polydispersity index (PdI), ζ-potential (mV), mRNA encapsulation rate (%), and mRNA concentration (μg / μL) of the PCSK9-targeted genome editing lipid nanoparticles are shown in Table 10.

[0359]

[0360] Next, the prepared PCSK9-targeted genome editing lipid nanoparticles were administered to Balb / c mice (4-week-old female) via the tail vein (0.3, 1.0, 2.0 mg RNA / kg). Ten days after administration, the mice were euthanized and blood was collected from the inferior vena cava (N = 3-6). The blood was left to stand at room temperature for 1 hour, then centrifuged at 4°C and 1,000 x g for 10 minutes. The supernatant was collected and serum was obtained. Serum PCSK9 concentrations were measured using a commercially available ELISA kit (Mouse / Rat PCSK9 ELISA Kit, CircuLex). Standard curve samples were prepared by serial dilution from 6 ng / mL to 3, 1.5, 0.75, 0.375, 0.188, and 0.094 ng / mL, 300 μL each. For serum samples, serum was diluted 100-fold. 100 μL of standard curve samples and serum samples were applied to the plate and incubated at 25°C for 60 minutes with shaking at 300 rpm. The wells were washed four times, and 100 μL of HRP-conjugated Detection Antibody (CircuLex) was applied to each well. The plate was then incubated at 25°C for 60 minutes with shaking at 300 rpm. The wells were washed four times again, and 100 μL of Substrate Reagent (CircuLex) was applied to each well. The plate was protected from light with aluminum foil and incubated at 25°C for 10-20 minutes with shaking at 300 rpm. 100 μL of Stop Solution (CircuLex) was then applied, and the absorbance at 450 nm and 540 nm was measured using a spectrofluorometer (VarioskanLux, Thermo Fisher Scientific).

[0361] Figure 13 shows the measurement results of the amount of PCSK9 (ng / mL) in serum. A dose-dependent increase in PCSK9 knockout efficiency was observed, and 2.0 mg RNA / kg showed PCSK9 knockout activity of 90% or more. These results suggest that efficient genome editing by mRNA can be achieved by using lipid nanoparticles with TxT-5-5A14 as a constituent lipid as a carrier.

[0362] The sequences of the gRNAs used in the above examples are as follows:

[0363] mU represents 2'-O-methyluridine; mA represents 2'-O-methyladenosine; mC represents 2'-O-methylcytidine; mG represents 2'-O-methylguanosine; * represents a phosphorothioate bond. * represents 2'-O-methyluridine with a 3'-phosphorothioate linkage, and mA * represents 2'-O-methyladenosine with a 3'-phosphorothioate linkage, mC * represents a 2'-O-methyl cytidine with a 3'-phosphorothioate linkage.

Claims

1. A compound represented by the following general formula (I) or (I'): [In formula (I) and formula (I′), R 1 is represented by the following general formulas (T-1) to (T-3): (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, R 22 is a hydrocarbon group having 1 to 22 carbon atoms, R 23 is a hydrocarbon group having 1 to 22 carbon atoms, R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, R 25 is a hydrocarbon group having 1 to 22 carbon atoms, R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 and R 22 The sum of the carbon numbers of R is 8 or more, 23 and R 24 The sum of the carbon numbers of R is 6 or more, 25 and R 26 The sum of the carbon numbers of R is 6 or more. The black circles represent bonds. 1 may be the same or different groups; Z 1 is an alkylene group having 1 to 6 carbon atoms which may be substituted with one hydroxyalkyl group having 1 to 3 carbon atoms, or a single bond; X is -N(R 2 ) (R 3 ), or a 5- to 7-membered non-aromatic heterocyclic group (provided that the group is not bound by a carbon atom in Z 1 and the ring may be substituted with one or two hydrocarbon groups or amide groups having 1 to 4 carbon atoms; R 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group), and in formula (I), Z 2 is a linear alkylene group or cycloalkylene group having 4 to 6 carbon atoms; 2 may be the same or different groups; in formula (I'), s is 2, 3, or 4; and the three s's in one molecule may be the same or different numbers. A pH-sensitive cationic lipid comprising a compound represented by the following formula:

2. In the general formula (I) or (I′), -Z 1 -X is represented by the following formulas (H-1) to (H-8) and (H-16) to (H-26): The pH-sensitive cationic lipid according to claim 1, wherein the pH-sensitive cationic lipid is selected from the group consisting of:

3. Three R's in one molecule 1 The pH-sensitive cationic lipid of claim 1 , wherein all of are the same group.

4. The pH-sensitive cationic lipid according to claim 1, which is represented by the general formula (I') and wherein s is 2 or 3.

5. The above R 1 is represented by the following formula (A8), (A8β), (A10), (A12), (A12β), (A14), (A16), (A16β), (A16b), (A20), (A24), (E12), (E14), (A14β), (A24β), (A10L), (A12L), or (A14L): The pH-sensitive cationic lipid according to claim 1, which is any one of the groups represented by the following formula:

6. The pH-sensitive cationic lipid according to claim 1, having a pKa of 4.0 to 9.

0.

7. The pH-sensitive cationic lipid of claim 1, selected from the following compounds: and 8. A method for producing a pH-sensitive cationic lipid, comprising condensing a compound represented by the following general formula (A), a compound represented by the following general formula (B), and tris(hydroxymethyl)aminomethane to produce a pH-sensitive cationic lipid comprising a compound represented by the following general formula (I): [In the formula, R 1 is represented by the following general formulas (T-1) to (T-3): (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, R 22 is a hydrocarbon group having 1 to 22 carbon atoms, R 23 is a hydrocarbon group having 1 to 22 carbon atoms, R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, R 25 is a hydrocarbon group having 1 to 22 carbon atoms, R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 and R 22 The sum of the carbon numbers of R is 8 or more, 23 and R 24 The sum of the carbon numbers of R is 6 or more, 25 and R 26 The sum of the carbon numbers of is 6 or more. The black circle is a bond. 2 is a linear alkylene group or a cycloalkylene group having 4 to 6 carbon atoms; Z 1 is an alkylene group having 1 to 6 carbon atoms which may be substituted with one hydroxyalkyl group having 1 to 3 carbon atoms, or a single bond; X is -N(R 2 ) (R 3 ), or a 5- to 7-membered non-aromatic heterocyclic group (provided that the group is not bound by a carbon atom in Z 1 and the ring may be substituted with one or two hydrocarbon groups or amide groups having 1 to 4 carbon atoms; R 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group); 1 may be the same or different groups; in general formula (I), there are three Z 2 may be the same group or different groups.

9. Condensing a compound represented by the following general formula (A-0) with a compound represented by the following general formula (D) to produce a compound represented by the following general formula (A'): [In the formula, R 1 is represented by the following general formulas (T-1) to (T-3): (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, R 22 is a hydrocarbon group having 1 to 22 carbon atoms, R 23 is a hydrocarbon group having 1 to 22 carbon atoms, R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, R 25 is a hydrocarbon group having 1 to 22 carbon atoms, R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 and R 22 The sum of the carbon numbers of R is 8 or more, 23 and R 24 The sum of the carbon numbers of R is 6 or more, 25 and R 26 is 6 or more. A black circle is a bond.) A group represented by any one of the following formulas; and s is 2, 3, or 4. The method includes condensing a compound represented by the above general formula (A'), a compound represented by the following general formula (B), and tris(hydroxymethyl)aminomethane to produce a pH-sensitive cationic lipid composed of a compound represented by the following general formula (I'): [In the formula, R 1 and s are the same as above; in general formula (I′), R 1 may be the same or different groups; in the general formula (I′), three s in one molecule may be the same or different; Z 1 is an alkylene group having 1 to 6 carbon atoms which may be substituted with one hydroxyalkyl group having 1 to 3 carbon atoms, or a single bond; X is -N(R 2 ) (R 3 ), or a 5- to 7-membered non-aromatic heterocyclic group (provided that the group is not bound by a carbon atom in Z 1 and the ring may be substituted with one or two hydrocarbon groups or amide groups having 1 to 4 carbon atoms; R 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3 may be bonded to each other to form a 5-7 membered non-aromatic heterocycle (a hydrogen atom of the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom of the ring may be a carbon atom constituting another nitrogen-containing cyclic group). A method for producing a pH-sensitive cationic lipid.

10. A compound represented by the following general formula (C): [In the formula, R 2 and R 3 are each independently a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms in which one or two hydrogen atoms may be substituted with a phenyl group, a pyrrolyl group, a pyrimidyl group, or an indolyl group, and R 2 and R 3 may be bonded to each other to form a 5-7 membered non-aromatic heterocycle (a hydrogen atom in the ring may be substituted with a hydrocarbon group having 1 to 4 carbon atoms, an amide group, or a nitrogen-containing cyclic group; one carbon atom in the ring may be a carbon atom constituting another nitrogen-containing cyclic group)), and then N-[tris(hydroxymethyl)methyl]acrylamide is added to a compound represented by the following general formula (A) or general formula (A'): [In formula (A) and formula (A'), R 1 is represented by the following general formulas (T-1) to (T-3): (In the formula, R 21 is a hydrocarbon group having 1 to 22 carbon atoms, R 22 is a hydrocarbon group having 1 to 22 carbon atoms, R 23 is a hydrocarbon group having 1 to 22 carbon atoms, R 24 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms, R 25 is a hydrocarbon group having 1 to 22 carbon atoms, R 26 is a hydrogen atom or a hydrocarbon group having 1 to 22 carbon atoms. 21 and R 22 The sum of the carbon numbers of R is 8 or more, 23 and R 24 The sum of the carbon numbers of R is 6 or more, 25 and R 26 The sum of the carbon numbers of is 6 or more. A black circle is a bond. 2 is a linear alkylene group or cycloalkylene group having 4 to 6 carbon atoms, and in formula (A'), s is 2, 3, or 4. [In formula (I-a) and formula (I′-a), R 1 , R 2 and R 3 is the same as above; R 1 may be the same or different groups, and in formula (I-a), Z 2 is the same as defined above, and in formula (I'-a), s is the same as defined above.

11. A lipid nanoparticle comprising a pH-sensitive cationic lipid according to any one of claims 1 to 7.

12. The lipid nanoparticle of claim 11, further comprising a sterol and a polyalkylene glycol-modified lipid.

13. The lipid nanoparticle of claim 11, further comprising phosphatidylcholine.

14. The lipid nanoparticle of claim 11, which contains a nucleic acid.

15. The lipid nanoparticle described in claim 14, wherein the nucleic acid is siRNA, mRNA, gRNA, or plasmid DNA.

16. A pharmaceutical composition comprising, as an active ingredient, lipid nanoparticles containing the pH-sensitive cationic lipid according to any one of claims 1 to 7.

17. A pharmaceutical composition comprising as an active ingredient lipid nanoparticles containing the pH-sensitive cationic lipid according to any one of claims 1 to 7 and a nucleic acid.

18. The pharmaceutical composition according to claim 16, which is used in gene therapy.

19. A method for expressing an exogenous gene, comprising administering to a subject animal the lipid nanoparticles described in claim 14 encapsulating an exogenous gene to be expressed in a target cell, and expressing the exogenous gene in the target cell of the subject animal.

Citation Information

Patent Citations

  • Vector for nuclear transport of substance

    WO2007102481A1

  • Optimized method for delivering dsRNA targeting the PCSK9 gene

    JP2011511004A

  • Lipid nanoparticle

    JP2022178879A

  • Improved lipid formulation

    WO2010088537A2

  • Flow channel structure and lipid particle or micelle formation method using same

    WO2018190423A1

Cited By

  • Cationic lipid

    WO2026134325A1